Search Results For:
- No search criteria provided
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Product development partnership
Vaccine
Early clinical (through Phase 2)
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
AUTM Model Inter-Institutional Research Collaboration Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Business model | Benefit sharing
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Industry
Drug
Preclinical
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
BMGF - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
BMGF - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
Industry
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
Government
Industry
Funder
Government
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Cellscript - BioNTech mRNA Technology Patent Sublicense
2016
Industry
Vaccine
Preclinical
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Business model | Benefit sharing
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Multilateral organization
Diagnostic
Commercialization
- Equitable Access | Affordable pricing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
WHO - Manufacturer, Ebola Products Collaboration LOA Template
2015
Multilateral organization
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
EDCTP2 Policy on Clinical Trials Registration, Publication, and Data Sharing
2018
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
Gates Foundation Sample Grant Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Business model | Payment Structures
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Indemnification & liability
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Liability | Representations & Warranties
Lambert Toolkit, Consortium Agreement D Template
2019
Academic institution
Industry
Industry
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Termination & withdrawal
Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Indemnification & liability
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MPP - AbbVie, HIV Antiretroviral License Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - AbbVie, HIV Antiretroviral Sublicense Agreement
2014
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - BMS - Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - BMS Sublicense & Tech Transfer Agreement
2017
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - Gilead, TDF License Agreement
2011
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - Pfizer, Sutezolid License Agreement
2019
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
2015
Academic institution
Multilateral organization
Multilateral organization
Device
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
MPP - ViiV, Dolutegravir License Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MSD - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
NIH - Non-Profit, Model License Agreement Terms
2017
Government
Multilateral organization
Product development partnership
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Liability | Representations & Warranties
- Term & termination | Term of agreement
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Academic Institution - Company, Research Collaboration Agreement
2016
Academic institution
Industry
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Access plans & principles
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Liability | Indemnification & liability
University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Multilateral organization
Drug
Preclinical
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
WHO Confidential Disclosure Agreement Template
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
GHIAA2019\MapguideSearch Object
(
[search_parameters] =>
[filters] => Array
(
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
)
[text_agreement_args] =>
[text_provision_args] =>
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT wpry_posts.*
FROM wpry_posts
WHERE 1=1 AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
ORDER BY wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:09:54
[post_modified_gmt] => 2022-05-24 09:09:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4807
[post_author] => 5
[post_date] => 2022-05-24 09:02:55
[post_date_gmt] => 2022-05-24 09:02:55
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:02:55
[post_modified_gmt] => 2022-05-24 09:02:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4806
[post_author] => 5
[post_date] => 2022-05-24 08:59:08
[post_date_gmt] => 2022-05-24 08:59:08
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:08
[post_modified_gmt] => 2022-05-24 08:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4805
[post_author] => 5
[post_date] => 2022-05-24 08:53:12
[post_date_gmt] => 2022-05-24 08:53:12
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:42
[post_modified_gmt] => 2022-05-24 08:59:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4804
[post_author] => 5
[post_date] => 2022-05-24 08:40:15
[post_date_gmt] => 2022-05-24 08:40:15
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:53:51
[post_modified_gmt] => 2022-05-24 08:53:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4802
[post_author] => 5
[post_date] => 2022-05-24 08:24:23
[post_date_gmt] => 2022-05-24 08:24:23
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:24:23
[post_modified_gmt] => 2022-05-24 08:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4801
[post_author] => 5
[post_date] => 2022-05-24 08:19:21
[post_date_gmt] => 2022-05-24 08:19:21
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:19:21
[post_modified_gmt] => 2022-05-24 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4800
[post_author] => 5
[post_date] => 2022-05-24 08:07:39
[post_date_gmt] => 2022-05-24 08:07:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:08:30
[post_modified_gmt] => 2022-05-24 08:08:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4797
[post_author] => 5
[post_date] => 2022-05-23 13:54:57
[post_date_gmt] => 2022-05-23 13:54:57
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 13:54:57
[post_modified_gmt] => 2022-05-23 13:54:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4796
[post_author] => 5
[post_date] => 2022-05-23 13:54:05
[post_date_gmt] => 2022-05-23 13:54:05
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:21:34
[post_modified_gmt] => 2022-05-23 14:21:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4704
[post_author] => 5
[post_date] => 2022-04-26 15:08:03
[post_date_gmt] => 2022-04-26 15:08:03
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:08:03
[post_modified_gmt] => 2022-04-26 15:08:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4704
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 4703
[post_author] => 5
[post_date] => 2022-04-26 14:56:55
[post_date_gmt] => 2022-04-26 14:56:55
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:56:55
[post_modified_gmt] => 2022-04-26 14:56:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4703
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 4702
[post_author] => 5
[post_date] => 2022-04-26 14:46:00
[post_date_gmt] => 2022-04-26 14:46:00
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:46:00
[post_modified_gmt] => 2022-04-26 14:46:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4702
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 4701
[post_author] => 5
[post_date] => 2022-04-26 14:30:45
[post_date_gmt] => 2022-04-26 14:30:45
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:30:45
[post_modified_gmt] => 2022-04-26 14:30:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4701
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 4700
[post_author] => 5
[post_date] => 2022-04-26 14:23:46
[post_date_gmt] => 2022-04-26 14:23:46
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:23:46
[post_modified_gmt] => 2022-04-26 14:23:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4700
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 4699
[post_author] => 5
[post_date] => 2022-04-26 14:06:18
[post_date_gmt] => 2022-04-26 14:06:18
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:06:18
[post_modified_gmt] => 2022-04-26 14:06:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4699
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 4698
[post_author] => 5
[post_date] => 2022-04-26 12:27:58
[post_date_gmt] => 2022-04-26 12:27:58
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 12:27:58
[post_modified_gmt] => 2022-04-26 12:27:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4698
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 4697
[post_author] => 5
[post_date] => 2022-04-26 12:05:54
[post_date_gmt] => 2022-04-26 12:05:54
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 12:10:05
[post_modified_gmt] => 2022-04-26 12:10:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4697
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 4696
[post_author] => 5
[post_date] => 2022-04-26 11:05:38
[post_date_gmt] => 2022-04-26 11:05:38
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:48:01
[post_modified_gmt] => 2022-04-26 14:48:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 4695
[post_author] => 5
[post_date] => 2022-04-26 09:54:07
[post_date_gmt] => 2022-04-26 09:54:07
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:46:53
[post_modified_gmt] => 2022-04-26 14:46:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4695
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 4691
[post_author] => 5
[post_date] => 2022-04-25 12:59:51
[post_date_gmt] => 2022-04-25 12:59:51
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:11:13
[post_modified_gmt] => 2022-04-26 15:11:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4691
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 4690
[post_author] => 5
[post_date] => 2022-04-25 12:53:48
[post_date_gmt] => 2022-04-25 12:53:48
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:11:27
[post_modified_gmt] => 2022-04-26 15:11:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4690
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 4689
[post_author] => 5
[post_date] => 2022-04-25 12:48:26
[post_date_gmt] => 2022-04-25 12:48:26
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:11:41
[post_modified_gmt] => 2022-04-26 15:11:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4689
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 4688
[post_author] => 5
[post_date] => 2022-04-25 12:44:13
[post_date_gmt] => 2022-04-25 12:44:13
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:11:58
[post_modified_gmt] => 2022-04-26 15:11:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4688
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 4687
[post_author] => 5
[post_date] => 2022-04-25 12:41:22
[post_date_gmt] => 2022-04-25 12:41:22
[post_content] =>
[post_title] => BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:12:16
[post_modified_gmt] => 2022-04-26 15:12:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4687
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 4686
[post_author] => 5
[post_date] => 2022-04-25 12:37:16
[post_date_gmt] => 2022-04-25 12:37:16
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:12:29
[post_modified_gmt] => 2022-04-26 15:12:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4686
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 4685
[post_author] => 5
[post_date] => 2022-04-25 12:29:54
[post_date_gmt] => 2022-04-25 12:29:54
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:12:55
[post_modified_gmt] => 2022-04-26 15:12:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4685
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 4684
[post_author] => 5
[post_date] => 2022-04-25 12:25:07
[post_date_gmt] => 2022-04-25 12:25:07
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:13:09
[post_modified_gmt] => 2022-04-26 15:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4684
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 4683
[post_author] => 5
[post_date] => 2022-04-25 12:03:48
[post_date_gmt] => 2022-04-25 12:03:48
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:10:52
[post_modified_gmt] => 2022-04-26 15:10:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4683
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 4682
[post_author] => 5
[post_date] => 2022-04-25 11:56:46
[post_date_gmt] => 2022-04-25 11:56:46
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:13:39
[post_modified_gmt] => 2022-04-26 15:13:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4682
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 4681
[post_author] => 5
[post_date] => 2022-04-25 11:39:24
[post_date_gmt] => 2022-04-25 11:39:24
[post_content] =>
[post_title] => BMGF – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:13:56
[post_modified_gmt] => 2022-04-26 15:13:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4681
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 4680
[post_author] => 5
[post_date] => 2022-04-25 11:17:54
[post_date_gmt] => 2022-04-25 11:17:54
[post_content] =>
[post_title] => BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:14:11
[post_modified_gmt] => 2022-04-26 15:14:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4680
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 4661
[post_author] => 5
[post_date] => 2022-04-20 08:13:06
[post_date_gmt] => 2022-04-20 08:13:06
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:13:06
[post_modified_gmt] => 2022-04-20 08:13:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4661
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:22:54
[post_modified_gmt] => 2022-04-18 13:22:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 4601
[post_author] => 5
[post_date] => 2022-04-18 10:40:48
[post_date_gmt] => 2022-04-18 10:40:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:44:46
[post_modified_gmt] => 2022-04-18 10:44:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4601
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:55:19
[post_modified_gmt] => 2022-04-18 13:55:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 4580
[post_author] => 5
[post_date] => 2022-03-31 14:34:38
[post_date_gmt] => 2022-03-31 14:34:38
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 16:12:17
[post_modified_gmt] => 2022-03-31 16:12:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4580
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 4519
[post_author] => 5
[post_date] => 2022-03-25 12:48:09
[post_date_gmt] => 2022-03-25 12:48:09
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-grant-terms-conditions
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-25 12:48:09
[post_modified_gmt] => 2022-03-25 12:48:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4519
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 4516
[post_author] => 5
[post_date] => 2022-03-23 09:07:57
[post_date_gmt] => 2022-03-23 09:07:57
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 09:09:43
[post_modified_gmt] => 2022-03-23 09:09:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4516
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 4491
[post_author] => 5
[post_date] => 2022-03-17 15:42:04
[post_date_gmt] => 2022-03-17 15:42:04
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 15:42:04
[post_modified_gmt] => 2022-03-17 15:42:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4491
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 4490
[post_author] => 5
[post_date] => 2022-03-17 15:37:26
[post_date_gmt] => 2022-03-17 15:37:26
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 15:38:01
[post_modified_gmt] => 2022-03-17 15:38:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4490
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 4489
[post_author] => 5
[post_date] => 2022-03-17 15:33:45
[post_date_gmt] => 2022-03-17 15:33:45
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 15:34:23
[post_modified_gmt] => 2022-03-17 15:34:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4489
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 4488
[post_author] => 5
[post_date] => 2022-03-17 15:11:54
[post_date_gmt] => 2022-03-17 15:11:54
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 10:48:00
[post_modified_gmt] => 2022-05-23 10:48:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4488
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 4487
[post_author] => 5
[post_date] => 2022-03-17 14:58:23
[post_date_gmt] => 2022-03-17 14:58:23
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 15:04:54
[post_modified_gmt] => 2022-03-17 15:04:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4487
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 4486
[post_author] => 5
[post_date] => 2022-03-17 14:50:08
[post_date_gmt] => 2022-03-17 14:50:08
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 14:50:08
[post_modified_gmt] => 2022-03-17 14:50:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4486
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 4485
[post_author] => 5
[post_date] => 2022-03-17 14:43:27
[post_date_gmt] => 2022-03-17 14:43:27
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 15:04:43
[post_modified_gmt] => 2022-03-17 15:04:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4485
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 4484
[post_author] => 5
[post_date] => 2022-03-17 13:56:19
[post_date_gmt] => 2022-03-17 13:56:19
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 13:56:19
[post_modified_gmt] => 2022-03-17 13:56:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4484
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 4483
[post_author] => 5
[post_date] => 2022-03-17 13:21:19
[post_date_gmt] => 2022-03-17 13:21:19
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 13:22:33
[post_modified_gmt] => 2022-03-17 13:22:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4483
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 4482
[post_author] => 5
[post_date] => 2022-03-17 12:43:13
[post_date_gmt] => 2022-03-17 12:43:13
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 12:43:13
[post_modified_gmt] => 2022-03-17 12:43:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 4481
[post_author] => 5
[post_date] => 2022-03-17 12:28:49
[post_date_gmt] => 2022-03-17 12:28:49
[post_content] =>
[post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 12:28:49
[post_modified_gmt] => 2022-03-17 12:28:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 4469
[post_author] => 5
[post_date] => 2022-03-17 10:55:42
[post_date_gmt] => 2022-03-17 10:55:42
[post_content] =>
[post_title] => Cellscript - BioNTech mRNA Technology Patent Sublicense
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cellscript-biontech-mrna-technology-patent-sublicense
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-17 15:54:23
[post_modified_gmt] => 2022-03-17 15:54:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4469
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 4223
[post_author] => 5
[post_date] => 2022-03-04 09:43:58
[post_date_gmt] => 2022-03-04 09:43:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 09:43:58
[post_modified_gmt] => 2022-03-04 09:43:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 4222
[post_author] => 5
[post_date] => 2022-03-04 09:14:41
[post_date_gmt] => 2022-03-04 09:14:41
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:51:38
[post_modified_gmt] => 2022-03-08 13:51:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 4221
[post_author] => 5
[post_date] => 2022-03-04 09:05:29
[post_date_gmt] => 2022-03-04 09:05:29
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 09:05:29
[post_modified_gmt] => 2022-03-04 09:05:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 4220
[post_author] => 5
[post_date] => 2022-03-04 08:47:04
[post_date_gmt] => 2022-03-04 08:47:04
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 08:47:04
[post_modified_gmt] => 2022-03-04 08:47:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 4219
[post_author] => 5
[post_date] => 2022-03-04 08:02:15
[post_date_gmt] => 2022-03-04 08:02:15
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 08:47:42
[post_modified_gmt] => 2022-03-04 08:47:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4218
[post_author] => 5
[post_date] => 2022-03-03 14:17:53
[post_date_gmt] => 2022-03-03 14:17:53
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 14:17:53
[post_modified_gmt] => 2022-03-03 14:17:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4217
[post_author] => 5
[post_date] => 2022-03-03 13:59:58
[post_date_gmt] => 2022-03-03 13:59:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 14:11:50
[post_modified_gmt] => 2022-03-03 14:11:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4216
[post_author] => 5
[post_date] => 2022-03-03 13:45:21
[post_date_gmt] => 2022-03-03 13:45:21
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 13:45:46
[post_modified_gmt] => 2022-03-03 13:45:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 4215
[post_author] => 5
[post_date] => 2022-03-03 13:31:56
[post_date_gmt] => 2022-03-03 13:31:56
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 13:42:58
[post_modified_gmt] => 2022-03-03 13:42:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:17:07
[post_modified_gmt] => 2022-03-21 13:17:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 10:58:00
[post_modified_gmt] => 2022-03-03 10:58:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 4212
[post_author] => 5
[post_date] => 2022-03-02 14:54:16
[post_date_gmt] => 2022-03-02 14:54:16
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:51:03
[post_modified_gmt] => 2022-03-08 13:51:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4212
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 4210
[post_author] => 5
[post_date] => 2022-03-02 13:14:31
[post_date_gmt] => 2022-03-02 13:14:31
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-02 13:14:31
[post_modified_gmt] => 2022-03-02 13:14:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 4209
[post_author] => 5
[post_date] => 2022-03-02 12:07:13
[post_date_gmt] => 2022-03-02 12:07:13
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 10:05:30
[post_modified_gmt] => 2022-03-04 10:05:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4209
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 4205
[post_author] => 5
[post_date] => 2022-02-28 15:24:19
[post_date_gmt] => 2022-02-28 15:24:19
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 15:24:19
[post_modified_gmt] => 2022-02-28 15:24:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 4204
[post_author] => 5
[post_date] => 2022-02-28 14:53:11
[post_date_gmt] => 2022-02-28 14:53:11
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:53:11
[post_modified_gmt] => 2022-02-28 14:53:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 4201
[post_author] => 5
[post_date] => 2022-02-28 13:33:22
[post_date_gmt] => 2022-02-28 13:33:22
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:46:09
[post_modified_gmt] => 2022-02-28 14:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 4200
[post_author] => 5
[post_date] => 2022-02-28 13:13:29
[post_date_gmt] => 2022-02-28 13:13:29
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:54:57
[post_modified_gmt] => 2022-03-08 13:54:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:17:00
[post_modified_gmt] => 2022-04-18 13:17:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 4159
[post_author] => 5
[post_date] => 2022-02-02 13:10:48
[post_date_gmt] => 2022-02-02 13:10:48
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:16:05
[post_modified_gmt] => 2022-04-18 13:16:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 4158
[post_author] => 5
[post_date] => 2022-02-02 13:00:08
[post_date_gmt] => 2022-02-02 13:00:08
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:15:30
[post_modified_gmt] => 2022-04-18 13:15:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 4157
[post_author] => 5
[post_date] => 2022-02-02 12:54:56
[post_date_gmt] => 2022-02-02 12:54:56
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:13:37
[post_modified_gmt] => 2022-04-18 13:13:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 4156
[post_author] => 5
[post_date] => 2022-02-02 12:36:42
[post_date_gmt] => 2022-02-02 12:36:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:51
[post_modified_gmt] => 2022-04-18 13:12:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 4155
[post_author] => 5
[post_date] => 2022-02-02 12:19:16
[post_date_gmt] => 2022-02-02 12:19:16
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:26
[post_modified_gmt] => 2022-04-18 13:12:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 4154
[post_author] => 5
[post_date] => 2022-02-02 12:13:41
[post_date_gmt] => 2022-02-02 12:13:41
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 12:13:41
[post_modified_gmt] => 2022-02-02 12:13:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4154
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 4153
[post_author] => 5
[post_date] => 2022-02-02 12:10:13
[post_date_gmt] => 2022-02-02 12:10:13
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:02:30
[post_modified_gmt] => 2022-04-18 13:02:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4153
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 4152
[post_author] => 5
[post_date] => 2022-02-02 11:51:54
[post_date_gmt] => 2022-02-02 11:51:54
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:02:06
[post_modified_gmt] => 2022-04-18 13:02:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 4151
[post_author] => 5
[post_date] => 2022-02-02 11:39:24
[post_date_gmt] => 2022-02-02 11:39:24
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:35
[post_modified_gmt] => 2022-04-18 13:01:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:03
[post_modified_gmt] => 2022-04-18 13:01:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:00:34
[post_modified_gmt] => 2022-04-18 13:00:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 4146
[post_author] => 5
[post_date] => 2022-02-02 07:28:42
[post_date_gmt] => 2022-02-02 07:28:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 12:57:05
[post_modified_gmt] => 2022-04-18 12:57:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4146
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 4141
[post_author] => 5
[post_date] => 2022-01-31 14:31:23
[post_date_gmt] => 2022-01-31 14:31:23
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:33:23
[post_modified_gmt] => 2022-01-31 14:33:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 4140
[post_author] => 5
[post_date] => 2022-01-31 14:22:03
[post_date_gmt] => 2022-01-31 14:22:03
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:11:05
[post_modified_gmt] => 2022-03-09 13:11:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 4139
[post_author] => 5
[post_date] => 2022-01-31 14:18:32
[post_date_gmt] => 2022-01-31 14:18:32
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 11:35:27
[post_modified_gmt] => 2022-02-11 11:35:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 4138
[post_author] => 5
[post_date] => 2022-01-31 14:09:33
[post_date_gmt] => 2022-01-31 14:09:33
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:09:33
[post_modified_gmt] => 2022-01-31 14:09:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4138
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 4137
[post_author] => 5
[post_date] => 2022-01-31 13:53:37
[post_date_gmt] => 2022-01-31 13:53:37
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:54:45
[post_modified_gmt] => 2022-01-31 13:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 4136
[post_author] => 5
[post_date] => 2022-01-31 13:42:47
[post_date_gmt] => 2022-01-31 13:42:47
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:42:47
[post_modified_gmt] => 2022-01-31 13:42:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 4135
[post_author] => 5
[post_date] => 2022-01-31 13:25:08
[post_date_gmt] => 2022-01-31 13:25:08
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:25:08
[post_modified_gmt] => 2022-01-31 13:25:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 4134
[post_author] => 5
[post_date] => 2022-01-31 12:56:28
[post_date_gmt] => 2022-01-31 12:56:28
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:56:28
[post_modified_gmt] => 2022-01-31 12:56:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:24:36
[post_modified_gmt] => 2022-01-31 12:24:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 16:31:13
[post_modified_gmt] => 2022-01-29 16:31:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 4130
[post_author] => 5
[post_date] => 2022-01-29 15:34:50
[post_date_gmt] => 2022-01-29 15:34:50
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 15:49:57
[post_modified_gmt] => 2022-01-29 15:49:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 4129
[post_author] => 5
[post_date] => 2022-01-28 14:43:06
[post_date_gmt] => 2022-01-28 14:43:06
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 16:21:05
[post_modified_gmt] => 2022-03-31 16:21:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:45:11
[post_modified_gmt] => 2022-01-28 13:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 4113
[post_author] => 5
[post_date] => 2022-01-19 09:21:03
[post_date_gmt] => 2022-01-19 09:21:03
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-inter-institutional-research-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 11:47:48
[post_modified_gmt] => 2022-02-11 11:47:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 4112
[post_author] => 5
[post_date] => 2022-01-18 14:43:23
[post_date_gmt] => 2022-01-18 14:43:23
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-inter-institutional-research-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 09:17:01
[post_modified_gmt] => 2022-01-19 09:17:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4112
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 4105
[post_author] => 5
[post_date] => 2022-01-18 13:30:40
[post_date_gmt] => 2022-01-18 13:30:40
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-inter-institutional-research-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 19:17:13
[post_modified_gmt] => 2022-01-18 19:17:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4105
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 4098
[post_author] => 5
[post_date] => 2022-01-12 14:27:12
[post_date_gmt] => 2022-01-12 14:27:12
[post_content] =>
[post_title] => Academic Institution – Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => academic-institution-company-research-collaboration-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-12 14:27:12
[post_modified_gmt] => 2022-01-12 14:27:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4098
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 4095
[post_author] => 5
[post_date] => 2022-01-12 13:39:41
[post_date_gmt] => 2022-01-12 13:39:41
[post_content] =>
[post_title] => Academic Institution – Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => academic-institution-company-research-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 10:25:54
[post_modified_gmt] => 2022-01-27 10:25:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4095
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 4094
[post_author] => 5
[post_date] => 2022-01-12 13:19:48
[post_date_gmt] => 2022-01-12 13:19:48
[post_content] =>
[post_title] => Academic Institution – Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => academic-institution-company-research-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-12 13:21:25
[post_modified_gmt] => 2022-01-12 13:21:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4094
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 4093
[post_author] => 5
[post_date] => 2022-01-12 13:01:38
[post_date_gmt] => 2022-01-12 13:01:38
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => academic-institution-company-research-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-12 13:01:38
[post_modified_gmt] => 2022-01-12 13:01:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4093
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 4092
[post_author] => 5
[post_date] => 2022-01-12 12:33:49
[post_date_gmt] => 2022-01-12 12:33:49
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => academic-institution-company-research-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-12 12:35:20
[post_modified_gmt] => 2022-01-12 12:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4092
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 4090
[post_author] => 5
[post_date] => 2022-01-12 11:48:32
[post_date_gmt] => 2022-01-12 11:48:32
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => academic-institution-company-research-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 10:27:15
[post_modified_gmt] => 2022-03-09 10:27:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4090
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 4089
[post_author] => 5
[post_date] => 2022-01-11 13:35:45
[post_date_gmt] => 2022-01-11 13:35:45
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 13:35:45
[post_modified_gmt] => 2022-01-11 13:35:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4089
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 4086
[post_author] => 5
[post_date] => 2022-01-11 12:13:55
[post_date_gmt] => 2022-01-11 12:13:55
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 12:27:50
[post_modified_gmt] => 2022-01-11 12:27:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4086
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 4085
[post_author] => 5
[post_date] => 2022-01-11 12:01:14
[post_date_gmt] => 2022-01-11 12:01:14
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 12:01:14
[post_modified_gmt] => 2022-01-11 12:01:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4085
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 4082
[post_author] => 5
[post_date] => 2022-01-11 09:06:56
[post_date_gmt] => 2022-01-11 09:06:56
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 09:07:31
[post_modified_gmt] => 2022-01-11 09:07:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4082
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 4081
[post_author] => 5
[post_date] => 2022-01-11 08:42:56
[post_date_gmt] => 2022-01-11 08:42:56
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 10:52:33
[post_modified_gmt] => 2022-01-27 10:52:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4081
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 4080
[post_author] => 5
[post_date] => 2022-01-11 08:32:58
[post_date_gmt] => 2022-01-11 08:32:58
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 15:17:30
[post_modified_gmt] => 2022-01-11 15:17:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4080
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 4079
[post_author] => 5
[post_date] => 2022-01-11 08:07:49
[post_date_gmt] => 2022-01-11 08:07:49
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 10:31:42
[post_modified_gmt] => 2022-03-09 10:31:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4079
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 4078
[post_author] => 5
[post_date] => 2022-01-11 07:42:00
[post_date_gmt] => 2022-01-11 07:42:00
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 07:42:00
[post_modified_gmt] => 2022-01-11 07:42:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4078
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 4077
[post_author] => 5
[post_date] => 2022-01-11 07:20:11
[post_date_gmt] => 2022-01-11 07:20:11
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:38:59
[post_modified_gmt] => 2022-04-01 10:38:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4077
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 4076
[post_author] => 5
[post_date] => 2022-01-11 06:36:58
[post_date_gmt] => 2022-01-11 06:36:58
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-22 14:41:35
[post_modified_gmt] => 2022-01-22 14:41:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4076
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 4075
[post_author] => 5
[post_date] => 2022-01-11 05:59:46
[post_date_gmt] => 2022-01-11 05:59:46
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 05:59:46
[post_modified_gmt] => 2022-01-11 05:59:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4075
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 4072
[post_author] => 5
[post_date] => 2022-01-08 13:16:04
[post_date_gmt] => 2022-01-08 13:16:04
[post_content] =>
[post_title] => University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-08 13:16:04
[post_modified_gmt] => 2022-01-08 13:16:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4072
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 4066
[post_author] => 5
[post_date] => 2022-01-07 11:35:15
[post_date_gmt] => 2022-01-07 11:35:15
[post_content] =>
[post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 11:35:15
[post_modified_gmt] => 2022-01-07 11:35:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4066
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 4065
[post_author] => 5
[post_date] => 2022-01-07 11:21:06
[post_date_gmt] => 2022-01-07 11:21:06
[post_content] =>
[post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 11:21:06
[post_modified_gmt] => 2022-01-07 11:21:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4065
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 4064
[post_author] => 5
[post_date] => 2022-01-07 10:57:29
[post_date_gmt] => 2022-01-07 10:57:29
[post_content] =>
[post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 10:57:29
[post_modified_gmt] => 2022-01-07 10:57:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4064
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 4063
[post_author] => 5
[post_date] => 2022-01-07 10:34:51
[post_date_gmt] => 2022-01-07 10:34:51
[post_content] =>
[post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 10:34:51
[post_modified_gmt] => 2022-01-07 10:34:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4063
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 4062
[post_author] => 5
[post_date] => 2022-01-07 10:03:12
[post_date_gmt] => 2022-01-07 10:03:12
[post_content] =>
[post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:12:47
[post_modified_gmt] => 2022-02-11 13:12:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4062
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 4061
[post_author] => 5
[post_date] => 2022-01-07 09:46:42
[post_date_gmt] => 2022-01-07 09:46:42
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 12:29:55
[post_modified_gmt] => 2022-03-21 12:29:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4061
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 4060
[post_author] => 5
[post_date] => 2022-01-07 09:40:49
[post_date_gmt] => 2022-01-07 09:40:49
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 09:40:49
[post_modified_gmt] => 2022-01-07 09:40:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4060
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 4058
[post_author] => 5
[post_date] => 2022-01-04 14:25:52
[post_date_gmt] => 2022-01-04 14:25:52
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:25:52
[post_modified_gmt] => 2022-01-04 14:25:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4058
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 4054
[post_author] => 5
[post_date] => 2022-01-03 11:45:52
[post_date_gmt] => 2022-01-03 11:45:52
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 11:46:09
[post_modified_gmt] => 2022-01-03 11:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4054
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 4051
[post_author] => 5
[post_date] => 2022-01-03 11:01:41
[post_date_gmt] => 2022-01-03 11:01:41
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 10:37:08
[post_modified_gmt] => 2022-03-09 10:37:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 4050
[post_author] => 5
[post_date] => 2022-01-03 10:49:32
[post_date_gmt] => 2022-01-03 10:49:32
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:56:55
[post_modified_gmt] => 2022-01-03 10:56:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4050
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 4047
[post_author] => 5
[post_date] => 2021-12-27 17:17:36
[post_date_gmt] => 2021-12-27 17:17:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:43:10
[post_modified_gmt] => 2022-01-03 10:43:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4047
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 4046
[post_author] => 5
[post_date] => 2021-12-27 17:10:47
[post_date_gmt] => 2021-12-27 17:10:47
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:10:47
[post_modified_gmt] => 2021-12-27 17:10:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4046
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 4045
[post_author] => 5
[post_date] => 2021-12-27 17:07:25
[post_date_gmt] => 2021-12-27 17:07:25
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:07:25
[post_modified_gmt] => 2021-12-27 17:07:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4045
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 4043
[post_author] => 5
[post_date] => 2021-12-27 16:47:54
[post_date_gmt] => 2021-12-27 16:47:54
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:47:54
[post_modified_gmt] => 2021-12-27 16:47:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4043
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 4042
[post_author] => 5
[post_date] => 2021-12-27 16:41:56
[post_date_gmt] => 2021-12-27 16:41:56
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 10:56:31
[post_modified_gmt] => 2022-01-27 10:56:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4042
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 4041
[post_author] => 5
[post_date] => 2021-12-27 16:28:21
[post_date_gmt] => 2021-12-27 16:28:21
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:28:42
[post_modified_gmt] => 2021-12-27 16:28:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4041
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 4040
[post_author] => 5
[post_date] => 2021-12-27 15:24:04
[post_date_gmt] => 2021-12-27 15:24:04
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-14 12:58:21
[post_modified_gmt] => 2022-03-14 12:58:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 4038
[post_author] => 5
[post_date] => 2021-12-27 15:08:30
[post_date_gmt] => 2021-12-27 15:08:30
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:22:28
[post_modified_gmt] => 2022-01-24 12:22:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4038
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 4036
[post_author] => 5
[post_date] => 2021-12-26 17:01:45
[post_date_gmt] => 2021-12-26 17:01:45
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:22:53
[post_modified_gmt] => 2022-02-11 13:22:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4036
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 4035
[post_author] => 5
[post_date] => 2021-12-26 16:47:36
[post_date_gmt] => 2021-12-26 16:47:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-26 16:47:36
[post_modified_gmt] => 2021-12-26 16:47:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4035
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 4032
[post_author] => 5
[post_date] => 2021-12-26 16:32:27
[post_date_gmt] => 2021-12-26 16:32:27
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-22 14:37:29
[post_modified_gmt] => 2022-01-22 14:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4032
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 4029
[post_author] => 5
[post_date] => 2021-12-21 12:22:08
[post_date_gmt] => 2021-12-21 12:22:08
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:10:58
[post_modified_gmt] => 2022-01-24 12:10:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4029
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 4028
[post_author] => 5
[post_date] => 2021-12-21 11:55:28
[post_date_gmt] => 2021-12-21 11:55:28
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-21 11:56:51
[post_modified_gmt] => 2021-12-21 11:56:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4028
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 4024
[post_author] => 5
[post_date] => 2021-12-15 15:33:17
[post_date_gmt] => 2021-12-15 15:33:17
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 15:33:17
[post_modified_gmt] => 2021-12-15 15:33:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4024
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 4022
[post_author] => 5
[post_date] => 2021-12-15 14:49:36
[post_date_gmt] => 2021-12-15 14:49:36
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:51:23
[post_modified_gmt] => 2021-12-15 14:51:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4022
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 4021
[post_author] => 5
[post_date] => 2021-12-15 14:31:00
[post_date_gmt] => 2021-12-15 14:31:00
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:31:00
[post_modified_gmt] => 2021-12-15 14:31:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4021
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 4020
[post_author] => 5
[post_date] => 2021-12-15 14:24:47
[post_date_gmt] => 2021-12-15 14:24:47
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:24:47
[post_modified_gmt] => 2021-12-15 14:24:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4020
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 4017
[post_author] => 5
[post_date] => 2021-12-15 13:22:49
[post_date_gmt] => 2021-12-15 13:22:49
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 13:22:49
[post_modified_gmt] => 2021-12-15 13:22:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4017
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 4016
[post_author] => 5
[post_date] => 2021-12-15 13:20:07
[post_date_gmt] => 2021-12-15 13:20:07
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:34:02
[post_modified_gmt] => 2022-01-27 11:34:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4016
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 4014
[post_author] => 5
[post_date] => 2021-12-15 12:33:09
[post_date_gmt] => 2021-12-15 12:33:09
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:33:09
[post_modified_gmt] => 2021-12-15 12:33:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4014
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 4013
[post_author] => 5
[post_date] => 2021-12-15 12:16:20
[post_date_gmt] => 2021-12-15 12:16:20
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:17:01
[post_modified_gmt] => 2021-12-15 12:17:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4013
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 4012
[post_author] => 5
[post_date] => 2021-12-15 12:01:13
[post_date_gmt] => 2021-12-15 12:01:13
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:01:13
[post_modified_gmt] => 2021-12-15 12:01:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4012
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 4011
[post_author] => 5
[post_date] => 2021-12-14 15:21:54
[post_date_gmt] => 2021-12-14 15:21:54
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 11:48:20
[post_modified_gmt] => 2021-12-15 11:48:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4011
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 4009
[post_author] => 5
[post_date] => 2021-12-14 15:10:51
[post_date_gmt] => 2021-12-14 15:10:51
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:00:07
[post_modified_gmt] => 2022-03-09 11:00:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4009
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[152] => WP_Post Object
(
[ID] => 4007
[post_author] => 5
[post_date] => 2021-12-14 08:51:32
[post_date_gmt] => 2021-12-14 08:51:32
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 08:51:44
[post_modified_gmt] => 2021-12-14 08:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4007
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[153] => WP_Post Object
(
[ID] => 4006
[post_author] => 5
[post_date] => 2021-12-14 08:16:01
[post_date_gmt] => 2021-12-14 08:16:01
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 14:46:11
[post_modified_gmt] => 2022-03-23 14:46:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4006
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[154] => WP_Post Object
(
[ID] => 4004
[post_author] => 5
[post_date] => 2021-12-14 07:57:41
[post_date_gmt] => 2021-12-14 07:57:41
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 07:57:41
[post_modified_gmt] => 2021-12-14 07:57:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4004
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[155] => WP_Post Object
(
[ID] => 4003
[post_author] => 5
[post_date] => 2021-12-13 18:36:53
[post_date_gmt] => 2021-12-13 18:36:53
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:25:43
[post_modified_gmt] => 2022-02-11 13:25:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4003
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[156] => WP_Post Object
(
[ID] => 4002
[post_author] => 5
[post_date] => 2021-12-13 18:28:05
[post_date_gmt] => 2021-12-13 18:28:05
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:41:28
[post_modified_gmt] => 2021-12-13 18:41:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4002
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[157] => WP_Post Object
(
[ID] => 4001
[post_author] => 5
[post_date] => 2021-12-13 14:55:46
[post_date_gmt] => 2021-12-13 14:55:46
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:30:22
[post_modified_gmt] => 2021-12-13 18:30:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4001
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[158] => WP_Post Object
(
[ID] => 3997
[post_author] => 5
[post_date] => 2021-12-13 14:24:49
[post_date_gmt] => 2021-12-13 14:24:49
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 14:24:59
[post_modified_gmt] => 2021-12-13 14:24:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3997
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[159] => WP_Post Object
(
[ID] => 3914
[post_author] => 5
[post_date] => 2021-11-30 12:34:32
[post_date_gmt] => 2021-11-30 12:34:32
[post_content] =>
[post_title] => MPP – BMS Sublicense & Tech Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-bms-sublicense-tech-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 15:06:04
[post_modified_gmt] => 2021-11-30 15:06:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3914
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[160] => WP_Post Object
(
[ID] => 3909
[post_author] => 5
[post_date] => 2021-11-22 13:29:28
[post_date_gmt] => 2021-11-22 13:29:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:13:09
[post_modified_gmt] => 2022-03-09 11:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[161] => WP_Post Object
(
[ID] => 3908
[post_author] => 5
[post_date] => 2021-11-22 13:20:09
[post_date_gmt] => 2021-11-22 13:20:09
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:28:33
[post_modified_gmt] => 2022-02-11 13:28:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[162] => WP_Post Object
(
[ID] => 3906
[post_author] => 5
[post_date] => 2021-11-22 12:57:50
[post_date_gmt] => 2021-11-22 12:57:50
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:22:44
[post_modified_gmt] => 2022-01-31 15:22:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[163] => WP_Post Object
(
[ID] => 3904
[post_author] => 5
[post_date] => 2021-11-22 12:20:20
[post_date_gmt] => 2021-11-22 12:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:00
[post_modified_gmt] => 2022-01-31 15:23:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3904
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[164] => WP_Post Object
(
[ID] => 3903
[post_author] => 5
[post_date] => 2021-11-22 12:04:07
[post_date_gmt] => 2021-11-22 12:04:07
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:16
[post_modified_gmt] => 2022-01-31 15:23:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3903
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[165] => WP_Post Object
(
[ID] => 3901
[post_author] => 5
[post_date] => 2021-11-22 11:42:55
[post_date_gmt] => 2021-11-22 11:42:55
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:34
[post_modified_gmt] => 2022-01-31 15:23:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3901
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[166] => WP_Post Object
(
[ID] => 3900
[post_author] => 5
[post_date] => 2021-11-22 11:35:10
[post_date_gmt] => 2021-11-22 11:35:10
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:52
[post_modified_gmt] => 2022-01-31 15:23:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3900
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[167] => WP_Post Object
(
[ID] => 3899
[post_author] => 5
[post_date] => 2021-11-22 11:24:36
[post_date_gmt] => 2021-11-22 11:24:36
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:42:51
[post_modified_gmt] => 2022-03-21 13:42:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3899
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[168] => WP_Post Object
(
[ID] => 3898
[post_author] => 5
[post_date] => 2021-11-22 11:02:44
[post_date_gmt] => 2021-11-22 11:02:44
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:24:53
[post_modified_gmt] => 2022-01-31 15:24:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3898
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[169] => WP_Post Object
(
[ID] => 3897
[post_author] => 5
[post_date] => 2021-11-22 10:34:34
[post_date_gmt] => 2021-11-22 10:34:34
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:11
[post_modified_gmt] => 2022-01-31 15:25:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3897
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[170] => WP_Post Object
(
[ID] => 3896
[post_author] => 5
[post_date] => 2021-11-22 10:27:28
[post_date_gmt] => 2021-11-22 10:27:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:40
[post_modified_gmt] => 2022-01-31 15:25:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3896
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[171] => WP_Post Object
(
[ID] => 3895
[post_author] => 5
[post_date] => 2021-11-22 10:20:20
[post_date_gmt] => 2021-11-22 10:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 09:51:43
[post_modified_gmt] => 2022-04-01 09:51:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3895
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[172] => WP_Post Object
(
[ID] => 3892
[post_author] => 5
[post_date] => 2021-11-19 13:53:26
[post_date_gmt] => 2021-11-19 13:53:26
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:26:44
[post_modified_gmt] => 2022-01-31 15:26:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[173] => WP_Post Object
(
[ID] => 3891
[post_author] => 5
[post_date] => 2021-11-19 13:11:12
[post_date_gmt] => 2021-11-19 13:11:12
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:27:01
[post_modified_gmt] => 2022-01-31 15:27:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3891
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[174] => WP_Post Object
(
[ID] => 3890
[post_author] => 5
[post_date] => 2021-11-19 13:00:24
[post_date_gmt] => 2021-11-19 13:00:24
[post_content] =>
[post_title] => MSD - MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:27:21
[post_modified_gmt] => 2022-01-31 15:27:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[175] => WP_Post Object
(
[ID] => 3869
[post_author] => 5
[post_date] => 2021-11-19 12:55:06
[post_date_gmt] => 2021-11-19 12:55:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-02 15:02:14
[post_modified_gmt] => 2021-12-02 15:02:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[176] => WP_Post Object
(
[ID] => 3886
[post_author] => 5
[post_date] => 2021-11-18 16:36:37
[post_date_gmt] => 2021-11-18 16:36:37
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 06:09:26
[post_modified_gmt] => 2022-04-12 06:09:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3886
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[177] => WP_Post Object
(
[ID] => 3884
[post_author] => 5
[post_date] => 2021-11-18 16:17:51
[post_date_gmt] => 2021-11-18 16:17:51
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:17:21
[post_modified_gmt] => 2022-03-09 11:17:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3884
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[178] => WP_Post Object
(
[ID] => 3883
[post_author] => 5
[post_date] => 2021-11-18 16:10:24
[post_date_gmt] => 2021-11-18 16:10:24
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:48:26
[post_modified_gmt] => 2021-12-03 12:48:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3883
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[179] => WP_Post Object
(
[ID] => 3882
[post_author] => 5
[post_date] => 2021-11-18 16:01:06
[post_date_gmt] => 2021-11-18 16:01:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:49:07
[post_modified_gmt] => 2021-12-03 12:49:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3882
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[180] => WP_Post Object
(
[ID] => 3881
[post_author] => 5
[post_date] => 2021-11-18 15:52:45
[post_date_gmt] => 2021-11-18 15:52:45
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:52:45
[post_modified_gmt] => 2021-11-18 15:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3881
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[181] => WP_Post Object
(
[ID] => 3880
[post_author] => 5
[post_date] => 2021-11-18 15:50:26
[post_date_gmt] => 2021-11-18 15:50:26
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:50:26
[post_modified_gmt] => 2021-11-18 15:50:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3880
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[182] => WP_Post Object
(
[ID] => 3878
[post_author] => 5
[post_date] => 2021-11-18 15:08:19
[post_date_gmt] => 2021-11-18 15:08:19
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:08:19
[post_modified_gmt] => 2021-11-18 15:08:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3878
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[183] => WP_Post Object
(
[ID] => 3877
[post_author] => 5
[post_date] => 2021-11-18 15:05:16
[post_date_gmt] => 2021-11-18 15:05:16
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:39:09
[post_modified_gmt] => 2022-01-27 11:39:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[184] => WP_Post Object
(
[ID] => 3876
[post_author] => 5
[post_date] => 2021-11-18 14:51:40
[post_date_gmt] => 2021-11-18 14:51:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 14:51:40
[post_modified_gmt] => 2021-11-18 14:51:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3876
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[185] => WP_Post Object
(
[ID] => 3875
[post_author] => 5
[post_date] => 2021-11-18 14:43:39
[post_date_gmt] => 2021-11-18 14:43:39
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 10:50:23
[post_modified_gmt] => 2021-11-22 10:50:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3875
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[186] => WP_Post Object
(
[ID] => 3874
[post_author] => 5
[post_date] => 2021-11-18 14:29:06
[post_date_gmt] => 2021-11-18 14:29:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 08:08:10
[post_modified_gmt] => 2022-04-12 08:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3874
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[187] => WP_Post Object
(
[ID] => 3873
[post_author] => 5
[post_date] => 2021-11-18 14:05:12
[post_date_gmt] => 2021-11-18 14:05:12
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:22:45
[post_modified_gmt] => 2021-11-19 12:22:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[188] => WP_Post Object
(
[ID] => 3870
[post_author] => 5
[post_date] => 2021-11-18 12:58:35
[post_date_gmt] => 2021-11-18 12:58:35
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:25:29
[post_modified_gmt] => 2021-11-19 12:25:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[189] => WP_Post Object
(
[ID] => 3863
[post_author] => 5
[post_date] => 2021-11-05 14:19:38
[post_date_gmt] => 2021-11-05 14:19:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:42
[post_modified_gmt] => 2022-04-18 09:22:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3863
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[190] => WP_Post Object
(
[ID] => 3861
[post_author] => 5
[post_date] => 2021-11-05 13:59:54
[post_date_gmt] => 2021-11-05 13:59:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:26
[post_modified_gmt] => 2022-04-18 07:16:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3861
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[191] => WP_Post Object
(
[ID] => 3860
[post_author] => 5
[post_date] => 2021-11-05 13:51:48
[post_date_gmt] => 2021-11-05 13:51:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:48
[post_modified_gmt] => 2022-04-18 07:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3860
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[192] => WP_Post Object
(
[ID] => 3859
[post_author] => 5
[post_date] => 2021-11-05 13:44:47
[post_date_gmt] => 2021-11-05 13:44:47
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:28:57
[post_modified_gmt] => 2022-04-18 07:28:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3859
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[193] => WP_Post Object
(
[ID] => 3858
[post_author] => 5
[post_date] => 2021-11-05 13:39:37
[post_date_gmt] => 2021-11-05 13:39:37
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:54:11
[post_modified_gmt] => 2022-04-18 07:54:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3858
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[194] => WP_Post Object
(
[ID] => 3857
[post_author] => 5
[post_date] => 2021-11-05 13:37:12
[post_date_gmt] => 2021-11-05 13:37:12
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:41:41
[post_modified_gmt] => 2022-04-18 07:41:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3857
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[195] => WP_Post Object
(
[ID] => 3856
[post_author] => 5
[post_date] => 2021-11-05 13:12:38
[post_date_gmt] => 2021-11-05 13:12:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:11:42
[post_modified_gmt] => 2022-04-18 08:11:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3856
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[196] => WP_Post Object
(
[ID] => 3855
[post_author] => 5
[post_date] => 2021-11-05 13:10:25
[post_date_gmt] => 2021-11-05 13:10:25
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:05:19
[post_modified_gmt] => 2022-04-18 08:05:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3855
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[197] => WP_Post Object
(
[ID] => 3854
[post_author] => 5
[post_date] => 2021-11-05 13:03:41
[post_date_gmt] => 2021-11-05 13:03:41
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:15:00
[post_modified_gmt] => 2022-04-18 08:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3854
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[198] => WP_Post Object
(
[ID] => 3852
[post_author] => 5
[post_date] => 2021-11-05 12:43:57
[post_date_gmt] => 2021-11-05 12:43:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:33:20
[post_modified_gmt] => 2022-04-18 08:33:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3852
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[199] => WP_Post Object
(
[ID] => 3851
[post_author] => 5
[post_date] => 2021-11-05 12:41:54
[post_date_gmt] => 2021-11-05 12:41:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:45:20
[post_modified_gmt] => 2022-04-18 08:45:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3851
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[200] => WP_Post Object
(
[ID] => 3849
[post_author] => 5
[post_date] => 2021-11-05 12:30:09
[post_date_gmt] => 2021-11-05 12:30:09
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:52:12
[post_modified_gmt] => 2022-04-18 08:52:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3849
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[201] => WP_Post Object
(
[ID] => 3848
[post_author] => 5
[post_date] => 2021-11-05 12:27:44
[post_date_gmt] => 2021-11-05 12:27:44
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:58:14
[post_modified_gmt] => 2022-04-18 08:58:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3848
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[202] => WP_Post Object
(
[ID] => 3847
[post_author] => 5
[post_date] => 2021-11-05 12:25:40
[post_date_gmt] => 2021-11-05 12:25:40
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:07:16
[post_modified_gmt] => 2022-04-18 09:07:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3847
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[203] => WP_Post Object
(
[ID] => 3846
[post_author] => 5
[post_date] => 2021-11-05 12:14:17
[post_date_gmt] => 2021-11-05 12:14:17
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:08:02
[post_modified_gmt] => 2022-04-18 09:08:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3846
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[204] => WP_Post Object
(
[ID] => 3845
[post_author] => 5
[post_date] => 2021-11-05 11:56:34
[post_date_gmt] => 2021-11-05 11:56:34
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:20:20
[post_modified_gmt] => 2022-04-18 09:20:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3845
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[205] => WP_Post Object
(
[ID] => 3819
[post_author] => 6
[post_date] => 2021-09-15 12:17:55
[post_date_gmt] => 2021-09-15 12:17:55
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 11:45:22
[post_modified_gmt] => 2021-12-15 11:45:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3819
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[206] => WP_Post Object
(
[ID] => 3812
[post_author] => 5
[post_date] => 2021-09-10 12:44:57
[post_date_gmt] => 2021-09-10 12:44:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:13:50
[post_modified_gmt] => 2022-04-20 09:13:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3812
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[207] => WP_Post Object
(
[ID] => 3810
[post_author] => 5
[post_date] => 2021-09-10 12:21:33
[post_date_gmt] => 2021-09-10 12:21:33
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:11:54
[post_modified_gmt] => 2022-04-20 07:11:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3810
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[208] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:19:45
[post_modified_gmt] => 2022-04-20 09:19:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[209] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:24:05
[post_modified_gmt] => 2022-04-20 07:24:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[210] => WP_Post Object
(
[ID] => 3807
[post_author] => 5
[post_date] => 2021-09-10 11:55:25
[post_date_gmt] => 2021-09-10 11:55:25
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:42:12
[post_modified_gmt] => 2022-04-20 07:42:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[211] => WP_Post Object
(
[ID] => 3806
[post_author] => 5
[post_date] => 2021-09-10 11:47:18
[post_date_gmt] => 2021-09-10 11:47:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:16:48
[post_modified_gmt] => 2022-04-20 09:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[212] => WP_Post Object
(
[ID] => 3805
[post_author] => 5
[post_date] => 2021-09-10 11:33:53
[post_date_gmt] => 2021-09-10 11:33:53
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:46:59
[post_modified_gmt] => 2022-04-20 07:46:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[213] => WP_Post Object
(
[ID] => 3804
[post_author] => 5
[post_date] => 2021-09-10 11:20:59
[post_date_gmt] => 2021-09-10 11:20:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:50:11
[post_modified_gmt] => 2022-04-20 07:50:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[214] => WP_Post Object
(
[ID] => 3803
[post_author] => 5
[post_date] => 2021-09-10 10:54:42
[post_date_gmt] => 2021-09-10 10:54:42
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:51:06
[post_modified_gmt] => 2022-04-20 07:51:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3803
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[215] => WP_Post Object
(
[ID] => 3802
[post_author] => 5
[post_date] => 2021-09-10 10:45:57
[post_date_gmt] => 2021-09-10 10:45:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:54:14
[post_modified_gmt] => 2022-04-20 07:54:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[216] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:05:17
[post_modified_gmt] => 2022-04-20 08:05:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[217] => WP_Post Object
(
[ID] => 3800
[post_author] => 5
[post_date] => 2021-09-10 10:25:59
[post_date_gmt] => 2021-09-10 10:25:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:35:52
[post_modified_gmt] => 2022-04-20 08:35:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[218] => WP_Post Object
(
[ID] => 3799
[post_author] => 5
[post_date] => 2021-09-10 10:07:18
[post_date_gmt] => 2021-09-10 10:07:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:44:40
[post_modified_gmt] => 2022-04-20 08:44:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3799
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[219] => WP_Post Object
(
[ID] => 3798
[post_author] => 5
[post_date] => 2021-09-10 10:02:07
[post_date_gmt] => 2021-09-10 10:02:07
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:46:03
[post_modified_gmt] => 2022-04-20 08:46:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[220] => WP_Post Object
(
[ID] => 3797
[post_author] => 5
[post_date] => 2021-09-10 09:54:44
[post_date_gmt] => 2021-09-10 09:54:44
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:53:13
[post_modified_gmt] => 2022-04-20 08:53:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[221] => WP_Post Object
(
[ID] => 3796
[post_author] => 5
[post_date] => 2021-09-10 09:03:43
[post_date_gmt] => 2021-09-10 09:03:43
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:07:03
[post_modified_gmt] => 2022-04-20 09:07:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[222] => WP_Post Object
(
[ID] => 3792
[post_author] => 5
[post_date] => 2021-09-09 14:23:13
[post_date_gmt] => 2021-09-09 14:23:13
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 12:44:33
[post_modified_gmt] => 2022-03-09 12:44:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3792
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[223] => WP_Post Object
(
[ID] => 3791
[post_author] => 5
[post_date] => 2021-09-09 14:18:44
[post_date_gmt] => 2021-09-09 14:18:44
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:00:35
[post_modified_gmt] => 2021-11-04 09:00:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3791
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[224] => WP_Post Object
(
[ID] => 3789
[post_author] => 5
[post_date] => 2021-09-09 14:07:30
[post_date_gmt] => 2021-09-09 14:07:30
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:42:42
[post_modified_gmt] => 2022-01-27 11:42:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3789
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[225] => WP_Post Object
(
[ID] => 3788
[post_author] => 5
[post_date] => 2021-09-09 14:00:40
[post_date_gmt] => 2021-09-09 14:00:40
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:02:12
[post_modified_gmt] => 2021-11-04 09:02:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3788
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[226] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:55:09
[post_modified_gmt] => 2022-03-21 13:55:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[227] => WP_Post Object
(
[ID] => 3785
[post_author] => 5
[post_date] => 2021-09-09 13:10:11
[post_date_gmt] => 2021-09-09 13:10:11
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:04:36
[post_modified_gmt] => 2021-11-04 09:04:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3785
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[228] => WP_Post Object
(
[ID] => 3784
[post_author] => 5
[post_date] => 2021-09-09 13:03:52
[post_date_gmt] => 2021-09-09 13:03:52
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:12
[post_modified_gmt] => 2021-11-04 09:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3784
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[229] => WP_Post Object
(
[ID] => 3783
[post_author] => 5
[post_date] => 2021-09-09 12:41:47
[post_date_gmt] => 2021-09-09 12:41:47
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:50
[post_modified_gmt] => 2021-11-04 09:05:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3783
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[230] => WP_Post Object
(
[ID] => 3782
[post_author] => 5
[post_date] => 2021-09-09 12:36:36
[post_date_gmt] => 2021-09-09 12:36:36
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:50:50
[post_modified_gmt] => 2022-03-28 10:50:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[231] => WP_Post Object
(
[ID] => 3781
[post_author] => 5
[post_date] => 2021-09-09 12:29:54
[post_date_gmt] => 2021-09-09 12:29:54
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:18:43
[post_modified_gmt] => 2021-11-23 14:18:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3781
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[232] => WP_Post Object
(
[ID] => 3778
[post_author] => 5
[post_date] => 2021-09-09 11:52:53
[post_date_gmt] => 2021-09-09 11:52:53
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:35:12
[post_modified_gmt] => 2021-12-06 12:35:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3778
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[233] => WP_Post Object
(
[ID] => 3769
[post_author] => 5
[post_date] => 2021-09-02 14:55:06
[post_date_gmt] => 2021-09-02 14:55:06
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-novavax-covid-19-vaccine-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-02 15:00:21
[post_modified_gmt] => 2021-12-02 15:00:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3769
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[234] => WP_Post Object
(
[ID] => 3768
[post_author] => 5
[post_date] => 2021-09-02 14:27:00
[post_date_gmt] => 2021-09-02 14:27:00
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:19:56
[post_modified_gmt] => 2021-12-03 14:19:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3768
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[235] => WP_Post Object
(
[ID] => 3765
[post_author] => 5
[post_date] => 2021-09-01 14:09:03
[post_date_gmt] => 2021-09-01 14:09:03
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:49:00
[post_modified_gmt] => 2022-03-28 10:49:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[236] => WP_Post Object
(
[ID] => 3764
[post_author] => 5
[post_date] => 2021-09-01 12:17:32
[post_date_gmt] => 2021-09-01 12:17:32
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:15:32
[post_modified_gmt] => 2021-11-23 14:15:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3764
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[237] => WP_Post Object
(
[ID] => 3758
[post_author] => 5
[post_date] => 2021-08-26 12:04:03
[post_date_gmt] => 2021-08-26 12:04:03
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:43:14
[post_modified_gmt] => 2022-03-28 10:43:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[238] => WP_Post Object
(
[ID] => 3757
[post_author] => 5
[post_date] => 2021-08-25 08:42:34
[post_date_gmt] => 2021-08-25 08:42:34
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:40:56
[post_modified_gmt] => 2021-11-22 15:40:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3757
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[239] => WP_Post Object
(
[ID] => 3756
[post_author] => 5
[post_date] => 2021-08-25 08:10:37
[post_date_gmt] => 2021-08-25 08:10:37
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 12:46:23
[post_modified_gmt] => 2022-03-09 12:46:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3756
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[240] => WP_Post Object
(
[ID] => 3755
[post_author] => 5
[post_date] => 2021-08-25 07:55:51
[post_date_gmt] => 2021-08-25 07:55:51
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 14:43:01
[post_modified_gmt] => 2022-01-24 14:43:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3755
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[241] => WP_Post Object
(
[ID] => 3754
[post_author] => 5
[post_date] => 2021-08-24 13:43:37
[post_date_gmt] => 2021-08-24 13:43:37
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 13:43:37
[post_modified_gmt] => 2021-08-24 13:43:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3754
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[242] => WP_Post Object
(
[ID] => 3753
[post_author] => 5
[post_date] => 2021-08-24 13:14:41
[post_date_gmt] => 2021-08-24 13:14:41
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 13:14:41
[post_modified_gmt] => 2021-08-24 13:14:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3753
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[243] => WP_Post Object
(
[ID] => 3751
[post_author] => 5
[post_date] => 2021-08-24 12:54:56
[post_date_gmt] => 2021-08-24 12:54:56
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:45:37
[post_modified_gmt] => 2022-01-27 11:45:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3751
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[244] => WP_Post Object
(
[ID] => 3749
[post_author] => 5
[post_date] => 2021-08-24 12:40:53
[post_date_gmt] => 2021-08-24 12:40:53
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 12:40:53
[post_modified_gmt] => 2021-08-24 12:40:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[245] => WP_Post Object
(
[ID] => 3748
[post_author] => 5
[post_date] => 2021-08-24 12:31:07
[post_date_gmt] => 2021-08-24 12:31:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:27:22
[post_modified_gmt] => 2022-03-28 10:27:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[246] => WP_Post Object
(
[ID] => 3747
[post_author] => 5
[post_date] => 2021-08-24 11:12:07
[post_date_gmt] => 2021-08-24 11:12:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 09:31:52
[post_modified_gmt] => 2021-12-03 09:31:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3747
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[247] => WP_Post Object
(
[ID] => 3746
[post_author] => 5
[post_date] => 2021-08-24 10:45:05
[post_date_gmt] => 2021-08-24 10:45:05
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 11:45:45
[post_modified_gmt] => 2021-12-03 11:45:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3746
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[248] => WP_Post Object
(
[ID] => 3744
[post_author] => 5
[post_date] => 2021-08-24 10:32:54
[post_date_gmt] => 2021-08-24 10:32:54
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:41:56
[post_modified_gmt] => 2021-11-22 15:41:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[249] => WP_Post Object
(
[ID] => 3743
[post_author] => 5
[post_date] => 2021-08-24 10:19:00
[post_date_gmt] => 2021-08-24 10:19:00
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 15:28:17
[post_modified_gmt] => 2021-12-06 15:28:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[250] => WP_Post Object
(
[ID] => 3741
[post_author] => 5
[post_date] => 2021-08-24 09:13:39
[post_date_gmt] => 2021-08-24 09:13:39
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:32:22
[post_modified_gmt] => 2022-01-04 12:32:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[251] => WP_Post Object
(
[ID] => 3736
[post_author] => 5
[post_date] => 2021-08-24 07:47:09
[post_date_gmt] => 2021-08-24 07:47:09
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:36:25
[post_modified_gmt] => 2022-05-24 09:36:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[252] => WP_Post Object
(
[ID] => 3726
[post_author] => 5
[post_date] => 2021-08-23 16:13:39
[post_date_gmt] => 2021-08-23 16:13:39
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 16:39:40
[post_modified_gmt] => 2022-03-31 16:39:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3726
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[253] => WP_Post Object
(
[ID] => 3725
[post_author] => 5
[post_date] => 2021-08-23 13:56:41
[post_date_gmt] => 2021-08-23 13:56:41
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-26 15:23:59
[post_modified_gmt] => 2022-01-26 15:23:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3725
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[254] => WP_Post Object
(
[ID] => 3724
[post_author] => 5
[post_date] => 2021-08-23 13:11:07
[post_date_gmt] => 2021-08-23 13:11:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-29 13:10:56
[post_modified_gmt] => 2022-03-29 13:10:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3724
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[255] => WP_Post Object
(
[ID] => 3722
[post_author] => 5
[post_date] => 2021-08-23 12:12:50
[post_date_gmt] => 2021-08-23 12:12:50
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 12:14:33
[post_modified_gmt] => 2021-08-23 12:14:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3722
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[256] => WP_Post Object
(
[ID] => 3698
[post_author] => 5
[post_date] => 2021-08-19 14:33:22
[post_date_gmt] => 2021-08-19 14:33:22
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-inter-institutional-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 19:16:34
[post_modified_gmt] => 2022-01-18 19:16:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3698
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[257] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:37:29
[post_modified_gmt] => 2022-01-18 12:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[258] => WP_Post Object
(
[ID] => 3694
[post_author] => 5
[post_date] => 2021-08-18 09:56:18
[post_date_gmt] => 2021-08-18 09:56:18
[post_content] =>
[post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-18 09:56:18
[post_modified_gmt] => 2021-08-18 09:56:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3694
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[259] => WP_Post Object
(
[ID] => 3692
[post_author] => 5
[post_date] => 2021-08-18 09:42:30
[post_date_gmt] => 2021-08-18 09:42:30
[post_content] =>
[post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-18 09:42:30
[post_modified_gmt] => 2021-08-18 09:42:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3692
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[260] => WP_Post Object
(
[ID] => 3691
[post_author] => 5
[post_date] => 2021-08-18 09:29:08
[post_date_gmt] => 2021-08-18 09:29:08
[post_content] =>
[post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:09:07
[post_modified_gmt] => 2021-12-03 12:09:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3691
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[261] => WP_Post Object
(
[ID] => 3689
[post_author] => 5
[post_date] => 2021-08-18 09:13:21
[post_date_gmt] => 2021-08-18 09:13:21
[post_content] =>
[post_title] => Gilead - Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-indian-generic-manufacturers-hcv-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-18 09:13:21
[post_modified_gmt] => 2021-08-18 09:13:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3689
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[262] => WP_Post Object
(
[ID] => 3495
[post_author] => 5
[post_date] => 2021-08-10 13:06:45
[post_date_gmt] => 2021-08-10 13:06:45
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dod-moderna-covid-19-vaccine-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:12:04
[post_modified_gmt] => 2021-11-29 14:12:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3495
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[263] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:24:35
[post_modified_gmt] => 2022-02-28 08:24:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[264] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:36
[post_modified_gmt] => 2022-04-18 09:22:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[265] => WP_Post Object
(
[ID] => 3434
[post_author] => 6
[post_date] => 2021-07-01 03:44:18
[post_date_gmt] => 2021-07-01 03:44:18
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:28:59
[post_modified_gmt] => 2022-04-18 09:28:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3434
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[266] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:32:11
[post_modified_gmt] => 2022-04-18 09:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[267] => WP_Post Object
(
[ID] => 3431
[post_author] => 6
[post_date] => 2021-07-01 03:38:49
[post_date_gmt] => 2021-07-01 03:38:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:41:10
[post_modified_gmt] => 2022-04-18 09:41:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3431
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[268] => WP_Post Object
(
[ID] => 3430
[post_author] => 6
[post_date] => 2021-07-01 03:27:51
[post_date_gmt] => 2021-07-01 03:27:51
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:45:31
[post_modified_gmt] => 2022-04-18 09:45:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3430
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[269] => WP_Post Object
(
[ID] => 3428
[post_author] => 6
[post_date] => 2021-07-01 03:24:00
[post_date_gmt] => 2021-07-01 03:24:00
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:47:22
[post_modified_gmt] => 2022-04-18 09:47:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3428
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[270] => WP_Post Object
(
[ID] => 3427
[post_author] => 6
[post_date] => 2021-07-01 03:22:23
[post_date_gmt] => 2021-07-01 03:22:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:49:38
[post_modified_gmt] => 2022-04-18 09:49:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[271] => WP_Post Object
(
[ID] => 3426
[post_author] => 6
[post_date] => 2021-07-01 03:06:23
[post_date_gmt] => 2021-07-01 03:06:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:28:05
[post_modified_gmt] => 2022-04-18 10:28:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[272] => WP_Post Object
(
[ID] => 3424
[post_author] => 6
[post_date] => 2021-07-01 03:03:57
[post_date_gmt] => 2021-07-01 03:03:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:47:10
[post_modified_gmt] => 2022-04-18 10:47:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[273] => WP_Post Object
(
[ID] => 3422
[post_author] => 6
[post_date] => 2021-07-01 02:58:21
[post_date_gmt] => 2021-07-01 02:58:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:48:25
[post_modified_gmt] => 2022-04-18 10:48:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[274] => WP_Post Object
(
[ID] => 3421
[post_author] => 6
[post_date] => 2021-07-01 02:56:30
[post_date_gmt] => 2021-07-01 02:56:30
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:51:44
[post_modified_gmt] => 2022-04-18 10:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3421
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[275] => WP_Post Object
(
[ID] => 3420
[post_author] => 6
[post_date] => 2021-07-01 02:52:05
[post_date_gmt] => 2021-07-01 02:52:05
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 11:01:10
[post_modified_gmt] => 2022-04-18 11:01:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3420
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[276] => WP_Post Object
(
[ID] => 3418
[post_author] => 5
[post_date] => 2021-06-30 19:06:19
[post_date_gmt] => 2021-06-30 19:06:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:03:49
[post_modified_gmt] => 2022-03-09 13:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3418
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[277] => WP_Post Object
(
[ID] => 3417
[post_author] => 5
[post_date] => 2021-06-30 19:04:34
[post_date_gmt] => 2021-06-30 19:04:34
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:39
[post_modified_gmt] => 2021-09-01 15:12:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3417
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[278] => WP_Post Object
(
[ID] => 3416
[post_author] => 5
[post_date] => 2021-06-30 19:02:19
[post_date_gmt] => 2021-06-30 19:02:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:57
[post_modified_gmt] => 2021-09-01 15:12:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3416
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[279] => WP_Post Object
(
[ID] => 3415
[post_author] => 5
[post_date] => 2021-06-30 19:00:20
[post_date_gmt] => 2021-06-30 19:00:20
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 12:40:36
[post_modified_gmt] => 2021-11-30 12:40:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3415
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[280] => WP_Post Object
(
[ID] => 3414
[post_author] => 5
[post_date] => 2021-06-30 18:54:43
[post_date_gmt] => 2021-06-30 18:54:43
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:08:59
[post_modified_gmt] => 2021-09-01 15:08:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3414
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[281] => WP_Post Object
(
[ID] => 3413
[post_author] => 5
[post_date] => 2021-06-30 18:52:08
[post_date_gmt] => 2021-06-30 18:52:08
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:10:41
[post_modified_gmt] => 2021-09-01 15:10:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3413
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[282] => WP_Post Object
(
[ID] => 3412
[post_author] => 5
[post_date] => 2021-06-30 18:48:13
[post_date_gmt] => 2021-06-30 18:48:13
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:32:40
[post_modified_gmt] => 2022-02-11 13:32:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3412
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[283] => WP_Post Object
(
[ID] => 3411
[post_author] => 5
[post_date] => 2021-06-30 18:39:53
[post_date_gmt] => 2021-06-30 18:39:53
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:11:28
[post_modified_gmt] => 2021-09-01 15:11:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3411
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[284] => WP_Post Object
(
[ID] => 3410
[post_author] => 5
[post_date] => 2021-06-30 18:37:02
[post_date_gmt] => 2021-06-30 18:37:02
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:09:38
[post_modified_gmt] => 2021-09-01 15:09:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3410
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[285] => WP_Post Object
(
[ID] => 3409
[post_author] => 5
[post_date] => 2021-06-30 18:34:04
[post_date_gmt] => 2021-06-30 18:34:04
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:58:15
[post_modified_gmt] => 2022-01-24 12:58:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3409
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[286] => WP_Post Object
(
[ID] => 3406
[post_author] => 5
[post_date] => 2021-06-30 18:25:58
[post_date_gmt] => 2021-06-30 18:25:58
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:11:44
[post_modified_gmt] => 2021-09-01 15:11:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3406
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[287] => WP_Post Object
(
[ID] => 3379
[post_author] => 5
[post_date] => 2021-06-30 17:56:54
[post_date_gmt] => 2021-06-30 17:56:54
[post_content] =>
[post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 17:56:54
[post_modified_gmt] => 2021-06-30 17:56:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3379
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[288] => WP_Post Object
(
[ID] => 3378
[post_author] => 5
[post_date] => 2021-06-30 17:55:17
[post_date_gmt] => 2021-06-30 17:55:17
[post_content] =>
[post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:34:59
[post_modified_gmt] => 2021-12-03 10:34:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3378
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[289] => WP_Post Object
(
[ID] => 3377
[post_author] => 5
[post_date] => 2021-06-30 17:20:14
[post_date_gmt] => 2021-06-30 17:20:14
[post_content] =>
[post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-25 12:45:09
[post_modified_gmt] => 2021-08-25 12:45:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3377
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[290] => WP_Post Object
(
[ID] => 3376
[post_author] => 5
[post_date] => 2021-06-30 16:38:25
[post_date_gmt] => 2021-06-30 16:38:25
[post_content] =>
[post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 16:38:25
[post_modified_gmt] => 2021-06-30 16:38:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3376
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[291] => WP_Post Object
(
[ID] => 3375
[post_author] => 5
[post_date] => 2021-06-30 16:36:27
[post_date_gmt] => 2021-06-30 16:36:27
[post_content] =>
[post_title] => BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:35:36
[post_modified_gmt] => 2021-08-10 10:35:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3375
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[292] => WP_Post Object
(
[ID] => 3369
[post_author] => 6
[post_date] => 2021-06-30 15:09:50
[post_date_gmt] => 2021-06-30 15:09:50
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 15:09:50
[post_modified_gmt] => 2021-06-30 15:09:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3369
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[293] => WP_Post Object
(
[ID] => 3372
[post_author] => 5
[post_date] => 2021-06-30 15:06:19
[post_date_gmt] => 2021-06-30 15:06:19
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:05:39
[post_modified_gmt] => 2022-03-09 13:05:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3372
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[294] => WP_Post Object
(
[ID] => 3370
[post_author] => 5
[post_date] => 2021-06-30 15:01:06
[post_date_gmt] => 2021-06-30 15:01:06
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:51:17
[post_modified_gmt] => 2022-01-27 11:51:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3370
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[295] => WP_Post Object
(
[ID] => 3368
[post_author] => 5
[post_date] => 2021-06-30 14:58:39
[post_date_gmt] => 2021-06-30 14:58:39
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:10:31
[post_modified_gmt] => 2021-08-24 08:10:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3368
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[296] => WP_Post Object
(
[ID] => 3367
[post_author] => 6
[post_date] => 2021-06-30 14:55:06
[post_date_gmt] => 2021-06-30 14:55:06
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 10:37:50
[post_modified_gmt] => 2021-07-21 10:37:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3367
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[297] => WP_Post Object
(
[ID] => 3366
[post_author] => 5
[post_date] => 2021-06-30 14:53:53
[post_date_gmt] => 2021-06-30 14:53:53
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:53:53
[post_modified_gmt] => 2021-06-30 14:53:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3366
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[298] => WP_Post Object
(
[ID] => 3365
[post_author] => 6
[post_date] => 2021-06-30 14:51:27
[post_date_gmt] => 2021-06-30 14:51:27
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:51:27
[post_modified_gmt] => 2021-06-30 14:51:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3365
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[299] => WP_Post Object
(
[ID] => 3364
[post_author] => 5
[post_date] => 2021-06-30 14:47:34
[post_date_gmt] => 2021-06-30 14:47:34
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-02 12:46:22
[post_modified_gmt] => 2021-09-02 12:46:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3364
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[300] => WP_Post Object
(
[ID] => 3362
[post_author] => 6
[post_date] => 2021-06-30 14:47:24
[post_date_gmt] => 2021-06-30 14:47:24
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 13:52:40
[post_modified_gmt] => 2021-07-21 13:52:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3362
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[301] => WP_Post Object
(
[ID] => 3359
[post_author] => 6
[post_date] => 2021-06-30 14:38:46
[post_date_gmt] => 2021-06-30 14:38:46
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:27:47
[post_modified_gmt] => 2021-12-03 10:27:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3359
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[302] => WP_Post Object
(
[ID] => 3361
[post_author] => 5
[post_date] => 2021-06-30 14:30:51
[post_date_gmt] => 2021-06-30 14:30:51
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:22:31
[post_modified_gmt] => 2021-12-03 14:22:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3361
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[303] => WP_Post Object
(
[ID] => 3360
[post_author] => 5
[post_date] => 2021-06-30 14:28:40
[post_date_gmt] => 2021-06-30 14:28:40
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:53:01
[post_modified_gmt] => 2021-12-07 11:53:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3360
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[304] => WP_Post Object
(
[ID] => 3356
[post_author] => 5
[post_date] => 2021-06-30 13:53:23
[post_date_gmt] => 2021-06-30 13:53:23
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:44:11
[post_modified_gmt] => 2022-03-28 10:44:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[305] => WP_Post Object
(
[ID] => 3358
[post_author] => 6
[post_date] => 2021-06-30 13:47:23
[post_date_gmt] => 2021-06-30 13:47:23
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-30 13:34:06
[post_modified_gmt] => 2021-07-30 13:34:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3358
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[306] => WP_Post Object
(
[ID] => 3357
[post_author] => 6
[post_date] => 2021-06-30 13:41:11
[post_date_gmt] => 2021-06-30 13:41:11
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:15:06
[post_modified_gmt] => 2022-03-28 10:15:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3357
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[307] => WP_Post Object
(
[ID] => 3355
[post_author] => 6
[post_date] => 2021-06-30 13:30:36
[post_date_gmt] => 2021-06-30 13:30:36
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 11:18:25
[post_modified_gmt] => 2022-03-31 11:18:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3355
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[308] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[309] => WP_Post Object
(
[ID] => 3353
[post_author] => 6
[post_date] => 2021-06-30 13:25:17
[post_date_gmt] => 2021-06-30 13:25:17
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-25 12:43:21
[post_modified_gmt] => 2021-08-25 12:43:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3353
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[310] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-30 12:46:37
[post_modified_gmt] => 2022-03-30 12:46:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[311] => WP_Post Object
(
[ID] => 3350
[post_author] => 6
[post_date] => 2021-06-30 13:18:18
[post_date_gmt] => 2021-06-30 13:18:18
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:25:06
[post_modified_gmt] => 2021-12-03 10:25:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3350
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[312] => WP_Post Object
(
[ID] => 3347
[post_author] => 6
[post_date] => 2021-06-30 13:12:31
[post_date_gmt] => 2021-06-30 13:12:31
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:24:42
[post_modified_gmt] => 2021-12-03 10:24:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3347
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[313] => WP_Post Object
(
[ID] => 3346
[post_author] => 6
[post_date] => 2021-06-30 13:07:59
[post_date_gmt] => 2021-06-30 13:07:59
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-18 11:30:25
[post_modified_gmt] => 2022-03-18 11:30:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3346
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[314] => WP_Post Object
(
[ID] => 3345
[post_author] => 6
[post_date] => 2021-06-30 13:04:52
[post_date_gmt] => 2021-06-30 13:04:52
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:17:30
[post_modified_gmt] => 2022-03-21 13:17:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3345
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[315] => WP_Post Object
(
[ID] => 3344
[post_author] => 6
[post_date] => 2021-06-30 13:02:36
[post_date_gmt] => 2021-06-30 13:02:36
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 10:49:09
[post_modified_gmt] => 2022-05-23 10:49:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3344
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[316] => WP_Post Object
(
[ID] => 3343
[post_author] => 6
[post_date] => 2021-06-30 12:57:07
[post_date_gmt] => 2021-06-30 12:57:07
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-21
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 12:57:07
[post_modified_gmt] => 2021-06-30 12:57:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3343
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[317] => WP_Post Object
(
[ID] => 3342
[post_author] => 6
[post_date] => 2021-06-30 12:50:17
[post_date_gmt] => 2021-06-30 12:50:17
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-04 13:23:43
[post_modified_gmt] => 2022-02-04 13:23:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3342
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[318] => WP_Post Object
(
[ID] => 3341
[post_author] => 6
[post_date] => 2021-06-30 12:44:43
[post_date_gmt] => 2021-06-30 12:44:43
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:54:49
[post_modified_gmt] => 2022-01-27 11:54:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3341
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[319] => WP_Post Object
(
[ID] => 3339
[post_author] => 6
[post_date] => 2021-06-30 12:37:28
[post_date_gmt] => 2021-06-30 12:37:28
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 12:37:28
[post_modified_gmt] => 2021-06-30 12:37:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3339
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[320] => WP_Post Object
(
[ID] => 3338
[post_author] => 6
[post_date] => 2021-06-30 12:27:08
[post_date_gmt] => 2021-06-30 12:27:08
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:37:11
[post_modified_gmt] => 2021-08-24 08:37:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3338
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[321] => WP_Post Object
(
[ID] => 3337
[post_author] => 6
[post_date] => 2021-06-30 12:21:58
[post_date_gmt] => 2021-06-30 12:21:58
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:17:32
[post_modified_gmt] => 2021-11-29 14:17:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3337
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[322] => WP_Post Object
(
[ID] => 3335
[post_author] => 6
[post_date] => 2021-06-30 12:20:18
[post_date_gmt] => 2021-06-30 12:20:18
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:35:14
[post_modified_gmt] => 2021-08-10 10:35:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3335
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[323] => WP_Post Object
(
[ID] => 3336
[post_author] => 6
[post_date] => 2021-06-30 12:18:57
[post_date_gmt] => 2021-06-30 12:18:57
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 12:18:57
[post_modified_gmt] => 2021-06-30 12:18:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3336
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[324] => WP_Post Object
(
[ID] => 3331
[post_author] => 6
[post_date] => 2021-06-30 12:09:31
[post_date_gmt] => 2021-06-30 12:09:31
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 12:16:00
[post_modified_gmt] => 2021-06-30 12:16:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3331
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[325] => WP_Post Object
(
[ID] => 3330
[post_author] => 6
[post_date] => 2021-06-30 12:06:21
[post_date_gmt] => 2021-06-30 12:06:21
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-18 08:52:13
[post_modified_gmt] => 2021-08-18 08:52:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3330
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[326] => WP_Post Object
(
[ID] => 3329
[post_author] => 6
[post_date] => 2021-06-30 12:04:02
[post_date_gmt] => 2021-06-30 12:04:02
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 14:22:13
[post_modified_gmt] => 2022-03-31 14:22:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3329
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[327] => WP_Post Object
(
[ID] => 3327
[post_author] => 6
[post_date] => 2021-06-30 11:47:34
[post_date_gmt] => 2021-06-30 11:47:34
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 14:35:37
[post_modified_gmt] => 2022-03-31 14:35:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3327
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[328] => WP_Post Object
(
[ID] => 3326
[post_author] => 6
[post_date] => 2021-06-30 11:35:26
[post_date_gmt] => 2021-06-30 11:35:26
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-04 14:02:08
[post_modified_gmt] => 2022-02-04 14:02:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3326
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[329] => WP_Post Object
(
[ID] => 3323
[post_author] => 6
[post_date] => 2021-06-30 11:15:16
[post_date_gmt] => 2021-06-30 11:15:16
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 14:27:42
[post_modified_gmt] => 2022-03-31 14:27:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3323
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[330] => WP_Post Object
(
[ID] => 3321
[post_author] => 6
[post_date] => 2021-06-30 11:12:36
[post_date_gmt] => 2021-06-30 11:12:36
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 13-commercial-benefits-arising-from-commercial-use-13-3-use-of-product-in-affected-territory-only-cepi-intends-to-take-reasonable-efforts-to-ensure-that-the-products-will-be-utilized-in-the-affected
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:16:51
[post_modified_gmt] => 2021-11-29 14:16:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3321
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[331] => WP_Post Object
(
[ID] => 3318
[post_author] => 6
[post_date] => 2021-06-30 10:46:25
[post_date_gmt] => 2021-06-30 10:46:25
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-04 13:02:05
[post_modified_gmt] => 2022-02-04 13:02:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3318
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[332] => WP_Post Object
(
[ID] => 3316
[post_author] => 6
[post_date] => 2021-06-30 10:25:45
[post_date_gmt] => 2021-06-30 10:25:45
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:36:52
[post_modified_gmt] => 2022-02-11 13:36:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3316
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[333] => WP_Post Object
(
[ID] => 3315
[post_author] => 6
[post_date] => 2021-06-30 10:19:01
[post_date_gmt] => 2021-06-30 10:19:01
[post_content] =>
[post_title] => CEPI - CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 10:19:01
[post_modified_gmt] => 2021-06-30 10:19:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[334] => WP_Post Object
(
[ID] => 3312
[post_author] => 6
[post_date] => 2021-06-30 10:06:34
[post_date_gmt] => 2021-06-30 10:06:34
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:00:53
[post_modified_gmt] => 2021-08-23 10:00:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3312
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[335] => WP_Post Object
(
[ID] => 3310
[post_author] => 6
[post_date] => 2021-06-30 10:01:40
[post_date_gmt] => 2021-06-30 10:01:40
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:01
[post_modified_gmt] => 2021-08-23 10:01:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3310
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[336] => WP_Post Object
(
[ID] => 3309
[post_author] => 6
[post_date] => 2021-06-30 09:51:28
[post_date_gmt] => 2021-06-30 09:51:28
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:05
[post_modified_gmt] => 2021-08-23 10:01:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3309
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[337] => WP_Post Object
(
[ID] => 3308
[post_author] => 6
[post_date] => 2021-06-30 09:48:24
[post_date_gmt] => 2021-06-30 09:48:24
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:10
[post_modified_gmt] => 2021-08-23 10:01:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3308
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[338] => WP_Post Object
(
[ID] => 3307
[post_author] => 6
[post_date] => 2021-06-30 09:44:19
[post_date_gmt] => 2021-06-30 09:44:19
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:13
[post_modified_gmt] => 2021-08-23 10:01:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3307
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[339] => WP_Post Object
(
[ID] => 3305
[post_author] => 6
[post_date] => 2021-06-30 09:35:10
[post_date_gmt] => 2021-06-30 09:35:10
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:17
[post_modified_gmt] => 2021-08-23 10:01:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3305
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[340] => WP_Post Object
(
[ID] => 3304
[post_author] => 6
[post_date] => 2021-06-30 09:30:56
[post_date_gmt] => 2021-06-30 09:30:56
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:21
[post_modified_gmt] => 2021-08-23 10:01:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[341] => WP_Post Object
(
[ID] => 3303
[post_author] => 6
[post_date] => 2021-06-30 09:26:40
[post_date_gmt] => 2021-06-30 09:26:40
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:26
[post_modified_gmt] => 2021-08-23 10:01:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3303
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[342] => WP_Post Object
(
[ID] => 3302
[post_author] => 6
[post_date] => 2021-06-30 09:21:45
[post_date_gmt] => 2021-06-30 09:21:45
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 3302
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:29
[post_modified_gmt] => 2021-08-23 10:01:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3302
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[343] => WP_Post Object
(
[ID] => 3221
[post_author] => 6
[post_date] => 2021-06-28 12:23:49
[post_date_gmt] => 2021-06-28 12:23:49
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:24
[post_modified_gmt] => 2021-08-23 09:51:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[344] => WP_Post Object
(
[ID] => 3220
[post_author] => 6
[post_date] => 2021-06-28 12:22:09
[post_date_gmt] => 2021-06-28 12:22:09
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:08:44
[post_modified_gmt] => 2022-03-09 13:08:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[345] => WP_Post Object
(
[ID] => 3219
[post_author] => 6
[post_date] => 2021-06-28 12:19:29
[post_date_gmt] => 2021-06-28 12:19:29
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:33
[post_modified_gmt] => 2021-08-23 09:51:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[346] => WP_Post Object
(
[ID] => 3218
[post_author] => 6
[post_date] => 2021-06-28 12:16:20
[post_date_gmt] => 2021-06-28 12:16:20
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:37
[post_modified_gmt] => 2021-08-23 09:51:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[347] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:41
[post_modified_gmt] => 2021-08-23 09:51:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[348] => WP_Post Object
(
[ID] => 3216
[post_author] => 6
[post_date] => 2021-06-28 12:11:22
[post_date_gmt] => 2021-06-28 12:11:22
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:45
[post_modified_gmt] => 2021-08-23 09:51:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[349] => WP_Post Object
(
[ID] => 3215
[post_author] => 6
[post_date] => 2021-06-28 12:07:55
[post_date_gmt] => 2021-06-28 12:07:55
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:48
[post_modified_gmt] => 2021-08-23 09:51:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[350] => WP_Post Object
(
[ID] => 3127
[post_author] => 6
[post_date] => 2021-06-03 15:08:41
[post_date_gmt] => 2021-06-03 15:08:41
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:45
[post_modified_gmt] => 2021-08-23 09:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[351] => WP_Post Object
(
[ID] => 3126
[post_author] => 6
[post_date] => 2021-06-03 15:05:40
[post_date_gmt] => 2021-06-03 15:05:40
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:49
[post_modified_gmt] => 2021-08-23 09:52:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[352] => WP_Post Object
(
[ID] => 3125
[post_author] => 6
[post_date] => 2021-06-03 15:03:17
[post_date_gmt] => 2021-06-03 15:03:17
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:13:17
[post_modified_gmt] => 2022-03-09 13:13:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[353] => WP_Post Object
(
[ID] => 3124
[post_author] => 6
[post_date] => 2021-06-03 15:01:23
[post_date_gmt] => 2021-06-03 15:01:23
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:56
[post_modified_gmt] => 2021-08-23 09:52:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[354] => WP_Post Object
(
[ID] => 3123
[post_author] => 6
[post_date] => 2021-06-03 14:51:22
[post_date_gmt] => 2021-06-03 14:51:22
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 13:12:13
[post_modified_gmt] => 2021-11-23 13:12:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[355] => WP_Post Object
(
[ID] => 3122
[post_author] => 6
[post_date] => 2021-06-03 14:45:44
[post_date_gmt] => 2021-06-03 14:45:44
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:08:08
[post_modified_gmt] => 2021-11-23 15:08:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[356] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:08
[post_modified_gmt] => 2021-08-23 09:53:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[357] => WP_Post Object
(
[ID] => 3120
[post_author] => 6
[post_date] => 2021-06-03 14:24:03
[post_date_gmt] => 2021-06-03 14:24:03
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:12
[post_modified_gmt] => 2021-08-23 09:53:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[358] => WP_Post Object
(
[ID] => 3119
[post_author] => 6
[post_date] => 2021-06-03 14:21:50
[post_date_gmt] => 2021-06-03 14:21:50
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:15
[post_modified_gmt] => 2021-08-23 09:53:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[359] => WP_Post Object
(
[ID] => 2972
[post_author] => 5
[post_date] => 2021-06-01 10:17:19
[post_date_gmt] => 2021-06-01 10:17:19
[post_content] =>
[post_title] => WHO Template Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:59:00
[post_modified_gmt] => 2022-01-27 11:59:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2972
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[360] => WP_Post Object
(
[ID] => 2956
[post_author] => 6
[post_date] => 2021-05-28 18:56:15
[post_date_gmt] => 2021-05-28 18:56:15
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:06
[post_modified_gmt] => 2021-08-23 10:02:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2956
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[361] => WP_Post Object
(
[ID] => 2961
[post_author] => 6
[post_date] => 2021-05-28 18:55:47
[post_date_gmt] => 2021-05-28 18:55:47
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:41:04
[post_modified_gmt] => 2021-11-23 12:41:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2961
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[362] => WP_Post Object
(
[ID] => 2965
[post_author] => 6
[post_date] => 2021-05-28 18:55:12
[post_date_gmt] => 2021-05-28 18:55:12
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:15
[post_modified_gmt] => 2021-08-23 10:02:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2965
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[363] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:17
[post_modified_gmt] => 2021-08-23 10:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[364] => WP_Post Object
(
[ID] => 2960
[post_author] => 6
[post_date] => 2021-05-28 18:53:36
[post_date_gmt] => 2021-05-28 18:53:36
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:20
[post_modified_gmt] => 2021-08-23 10:02:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2960
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[365] => WP_Post Object
(
[ID] => 2964
[post_author] => 6
[post_date] => 2021-05-28 18:53:11
[post_date_gmt] => 2021-05-28 18:53:11
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:24
[post_modified_gmt] => 2021-08-23 10:02:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2964
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[366] => WP_Post Object
(
[ID] => 2958
[post_author] => 6
[post_date] => 2021-05-28 18:52:54
[post_date_gmt] => 2021-05-28 18:52:54
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:13:48
[post_modified_gmt] => 2021-12-03 10:13:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2958
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[367] => WP_Post Object
(
[ID] => 2949
[post_author] => 6
[post_date] => 2021-05-28 18:52:06
[post_date_gmt] => 2021-05-28 18:52:06
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:37:55
[post_modified_gmt] => 2021-11-23 12:37:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2949
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[368] => WP_Post Object
(
[ID] => 2957
[post_author] => 6
[post_date] => 2021-05-28 18:51:39
[post_date_gmt] => 2021-05-28 18:51:39
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:00:44
[post_modified_gmt] => 2022-01-27 12:00:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2957
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[369] => WP_Post Object
(
[ID] => 2962
[post_author] => 6
[post_date] => 2021-05-28 18:50:18
[post_date_gmt] => 2021-05-28 18:50:18
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:38:17
[post_modified_gmt] => 2021-11-23 12:38:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2962
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[370] => WP_Post Object
(
[ID] => 2945
[post_author] => 6
[post_date] => 2021-05-28 14:03:27
[post_date_gmt] => 2021-05-28 14:03:27
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:13:02
[post_modified_gmt] => 2021-12-03 10:13:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2945
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[371] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:35:40
[post_modified_gmt] => 2022-02-28 08:35:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[372] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:59:23
[post_modified_gmt] => 2022-02-28 08:59:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[373] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 09:05:23
[post_modified_gmt] => 2022-02-28 09:05:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[374] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 09:23:17
[post_modified_gmt] => 2022-02-28 09:23:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[375] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:11:21
[post_modified_gmt] => 2022-04-01 10:11:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[376] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:45:33
[post_modified_gmt] => 2022-03-28 10:45:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[377] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 10:58:28
[post_modified_gmt] => 2022-02-28 10:58:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[378] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:01:15
[post_modified_gmt] => 2022-02-28 14:01:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[379] => WP_Post Object
(
[ID] => 2873
[post_author] => 6
[post_date] => 2021-05-11 15:17:08
[post_date_gmt] => 2021-05-11 15:17:08
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:50:47
[post_modified_gmt] => 2021-11-22 15:50:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[380] => WP_Post Object
(
[ID] => 2872
[post_author] => 6
[post_date] => 2021-05-11 15:14:24
[post_date_gmt] => 2021-05-11 15:14:24
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:00:31
[post_modified_gmt] => 2021-12-06 12:00:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2872
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[381] => WP_Post Object
(
[ID] => 2870
[post_author] => 6
[post_date] => 2021-05-11 15:07:59
[post_date_gmt] => 2021-05-11 15:07:59
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-15 09:15:21
[post_modified_gmt] => 2021-06-15 09:15:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[382] => WP_Post Object
(
[ID] => 2869
[post_author] => 6
[post_date] => 2021-05-11 14:53:04
[post_date_gmt] => 2021-05-11 14:53:04
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:15:00
[post_modified_gmt] => 2021-05-14 09:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[383] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 12:12:41
[post_modified_gmt] => 2022-05-24 12:12:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[384] => WP_Post Object
(
[ID] => 2824
[post_author] => 5
[post_date] => 2021-04-16 16:39:49
[post_date_gmt] => 2021-04-16 16:39:49
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:31:21
[post_modified_gmt] => 2022-01-27 12:31:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2824
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[385] => WP_Post Object
(
[ID] => 2823
[post_author] => 5
[post_date] => 2021-04-16 16:17:11
[post_date_gmt] => 2021-04-16 16:17:11
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:36:43
[post_modified_gmt] => 2022-01-18 12:36:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2823
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[386] => WP_Post Object
(
[ID] => 2822
[post_author] => 5
[post_date] => 2021-04-16 16:09:31
[post_date_gmt] => 2021-04-16 16:09:31
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:48:13
[post_modified_gmt] => 2022-01-18 12:48:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2822
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[387] => WP_Post Object
(
[ID] => 2820
[post_author] => 5
[post_date] => 2021-04-16 12:44:14
[post_date_gmt] => 2021-04-16 12:44:14
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:50:08
[post_modified_gmt] => 2022-01-18 12:50:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2820
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[388] => WP_Post Object
(
[ID] => 2744
[post_author] => 5
[post_date] => 2021-03-30 15:12:35
[post_date_gmt] => 2021-03-30 15:12:35
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:48:08
[post_modified_gmt] => 2021-08-12 13:48:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[389] => WP_Post Object
(
[ID] => 2749
[post_author] => 5
[post_date] => 2021-03-30 15:10:16
[post_date_gmt] => 2021-03-30 15:10:16
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:54:16
[post_modified_gmt] => 2021-08-12 13:54:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[390] => WP_Post Object
(
[ID] => 2748
[post_author] => 5
[post_date] => 2021-03-30 15:05:46
[post_date_gmt] => 2021-03-30 15:05:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2748
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:52:39
[post_modified_gmt] => 2021-08-12 13:52:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[391] => WP_Post Object
(
[ID] => 2743
[post_author] => 5
[post_date] => 2021-03-24 15:11:40
[post_date_gmt] => 2021-03-24 15:11:40
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:33:45
[post_modified_gmt] => 2022-01-27 12:33:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[392] => WP_Post Object
(
[ID] => 2742
[post_author] => 5
[post_date] => 2021-03-24 13:37:07
[post_date_gmt] => 2021-03-24 13:37:07
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:28:13
[post_modified_gmt] => 2021-08-12 12:28:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2742
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[393] => WP_Post Object
(
[ID] => 2741
[post_author] => 5
[post_date] => 2021-03-24 13:32:55
[post_date_gmt] => 2021-03-24 13:32:55
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:06:52
[post_modified_gmt] => 2021-11-23 15:06:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[394] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:47:55
[post_modified_gmt] => 2022-03-28 10:47:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[395] => WP_Post Object
(
[ID] => 2737
[post_author] => 5
[post_date] => 2021-03-24 13:00:46
[post_date_gmt] => 2021-03-24 13:00:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:45:35
[post_modified_gmt] => 2021-08-12 12:45:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2737
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[396] => WP_Post Object
(
[ID] => 2736
[post_author] => 5
[post_date] => 2021-03-23 18:15:15
[post_date_gmt] => 2021-03-23 18:15:15
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:50:37
[post_modified_gmt] => 2021-12-03 14:50:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[397] => WP_Post Object
(
[ID] => 2734
[post_author] => 5
[post_date] => 2021-03-23 18:01:22
[post_date_gmt] => 2021-03-23 18:01:22
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 10:29:04
[post_modified_gmt] => 2021-09-03 10:29:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2734
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[398] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 18:43:53
[post_modified_gmt] => 2022-01-04 18:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[399] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 09:35:45
[post_modified_gmt] => 2022-01-05 09:35:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[400] => WP_Post Object
(
[ID] => 2541
[post_author] => 5
[post_date] => 2021-03-12 18:11:14
[post_date_gmt] => 2021-03-12 18:11:14
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:49:36
[post_modified_gmt] => 2022-01-05 10:49:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2541
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[401] => WP_Post Object
(
[ID] => 2542
[post_author] => 5
[post_date] => 2021-03-12 14:21:07
[post_date_gmt] => 2021-03-12 14:21:07
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:17:48
[post_modified_gmt] => 2022-01-05 10:17:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2542
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[402] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:10:55
[post_modified_gmt] => 2022-03-28 10:10:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[403] => WP_Post Object
(
[ID] => 2545
[post_author] => 5
[post_date] => 2021-03-12 14:14:38
[post_date_gmt] => 2021-03-12 14:14:38
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:14:28
[post_modified_gmt] => 2022-03-09 13:14:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2545
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[404] => WP_Post Object
(
[ID] => 2547
[post_author] => 5
[post_date] => 2021-03-12 13:58:55
[post_date_gmt] => 2021-03-12 13:58:55
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:38:40
[post_modified_gmt] => 2022-01-27 12:38:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2547
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[405] => WP_Post Object
(
[ID] => 2549
[post_author] => 5
[post_date] => 2021-03-12 13:50:41
[post_date_gmt] => 2021-03-12 13:50:41
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 08:48:43
[post_modified_gmt] => 2022-01-05 08:48:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[406] => WP_Post Object
(
[ID] => 2553
[post_author] => 5
[post_date] => 2021-03-12 13:47:42
[post_date_gmt] => 2021-03-12 13:47:42
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:59:58
[post_modified_gmt] => 2022-01-05 10:59:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2553
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[407] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 12:14:51
[post_modified_gmt] => 2021-09-03 12:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[408] => WP_Post Object
(
[ID] => 2461
[post_author] => 5
[post_date] => 2021-02-25 15:23:35
[post_date_gmt] => 2021-02-25 15:23:35
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:19:55
[post_modified_gmt] => 2021-08-24 08:19:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[409] => WP_Post Object
(
[ID] => 2462
[post_author] => 5
[post_date] => 2021-02-25 15:23:19
[post_date_gmt] => 2021-02-25 15:23:19
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 13:28:17
[post_modified_gmt] => 2021-09-03 13:28:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[410] => WP_Post Object
(
[ID] => 2463
[post_author] => 5
[post_date] => 2021-02-25 15:22:52
[post_date_gmt] => 2021-02-25 15:22:52
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 13:35:23
[post_modified_gmt] => 2021-09-03 13:35:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2463
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[411] => WP_Post Object
(
[ID] => 2464
[post_author] => 5
[post_date] => 2021-02-25 15:21:51
[post_date_gmt] => 2021-02-25 15:21:51
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:13:03
[post_modified_gmt] => 2021-11-23 15:13:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2464
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[412] => WP_Post Object
(
[ID] => 2465
[post_author] => 5
[post_date] => 2021-02-25 15:21:32
[post_date_gmt] => 2021-02-25 15:21:32
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:40:25
[post_modified_gmt] => 2022-01-27 12:40:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2465
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[413] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:50:01
[post_modified_gmt] => 2022-03-28 10:50:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[414] => WP_Post Object
(
[ID] => 2467
[post_author] => 5
[post_date] => 2021-02-25 15:20:15
[post_date_gmt] => 2021-02-25 15:20:15
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:15:33
[post_modified_gmt] => 2022-03-09 13:15:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[415] => WP_Post Object
(
[ID] => 2470
[post_author] => 5
[post_date] => 2021-01-25 13:24:13
[post_date_gmt] => 2021-01-25 13:24:13
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 13:54:22
[post_modified_gmt] => 2022-03-28 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2470
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[416] => WP_Post Object
(
[ID] => 2473
[post_author] => 5
[post_date] => 2021-01-25 13:21:58
[post_date_gmt] => 2021-01-25 13:21:58
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:14:59
[post_modified_gmt] => 2022-01-04 14:14:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2473
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[417] => WP_Post Object
(
[ID] => 2474
[post_author] => 5
[post_date] => 2021-01-25 13:19:34
[post_date_gmt] => 2021-01-25 13:19:34
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:54:44
[post_modified_gmt] => 2022-01-04 12:54:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2474
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[418] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 11:57:00
[post_modified_gmt] => 2022-01-04 11:57:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[419] => WP_Post Object
(
[ID] => 2476
[post_author] => 5
[post_date] => 2021-01-25 13:18:09
[post_date_gmt] => 2021-01-25 13:18:09
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:42:48
[post_modified_gmt] => 2022-01-04 12:42:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2476
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[420] => WP_Post Object
(
[ID] => 2477
[post_author] => 5
[post_date] => 2021-01-25 13:16:23
[post_date_gmt] => 2021-01-25 13:16:23
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:38:40
[post_modified_gmt] => 2022-03-08 13:38:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2477
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[421] => WP_Post Object
(
[ID] => 2479
[post_author] => 5
[post_date] => 2021-01-25 13:12:32
[post_date_gmt] => 2021-01-25 13:12:32
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:42:15
[post_modified_gmt] => 2022-01-27 12:42:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[422] => WP_Post Object
(
[ID] => 2481
[post_author] => 5
[post_date] => 2021-01-25 13:11:08
[post_date_gmt] => 2021-01-25 13:11:08
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 10:39:14
[post_modified_gmt] => 2022-01-19 10:39:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[423] => WP_Post Object
(
[ID] => 2482
[post_author] => 5
[post_date] => 2021-01-25 13:09:37
[post_date_gmt] => 2021-01-25 13:09:37
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:23:50
[post_modified_gmt] => 2022-01-04 14:23:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[424] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 13:51:57
[post_modified_gmt] => 2022-01-04 13:51:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[425] => WP_Post Object
(
[ID] => 2454
[post_author] => 5
[post_date] => 2021-01-19 11:44:16
[post_date_gmt] => 2021-01-19 11:44:16
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:28:26
[post_modified_gmt] => 2021-11-23 14:28:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2454
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[426] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:12:55
[post_modified_gmt] => 2022-03-28 10:12:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[427] => WP_Post Object
(
[ID] => 2450
[post_author] => 5
[post_date] => 2021-01-19 11:04:23
[post_date_gmt] => 2021-01-19 11:04:23
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:46:34
[post_modified_gmt] => 2022-01-27 12:46:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2450
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[428] => WP_Post Object
(
[ID] => 2449
[post_author] => 5
[post_date] => 2021-01-19 10:47:27
[post_date_gmt] => 2021-01-19 10:47:27
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:29:46
[post_modified_gmt] => 2021-11-23 14:29:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2449
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[429] => WP_Post Object
(
[ID] => 2448
[post_author] => 5
[post_date] => 2021-01-19 10:24:45
[post_date_gmt] => 2021-01-19 10:24:45
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:29:52
[post_modified_gmt] => 2021-11-23 14:29:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2448
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[430] => WP_Post Object
(
[ID] => 2444
[post_author] => 5
[post_date] => 2021-01-19 09:27:20
[post_date_gmt] => 2021-01-19 09:27:20
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:42:37
[post_modified_gmt] => 2022-03-08 13:42:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2444
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[431] => WP_Post Object
(
[ID] => 2443
[post_author] => 5
[post_date] => 2021-01-19 09:14:03
[post_date_gmt] => 2021-01-19 09:14:03
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:17:16
[post_modified_gmt] => 2021-11-23 14:17:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2443
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[432] => WP_Post Object
(
[ID] => 2442
[post_author] => 5
[post_date] => 2021-01-19 06:56:32
[post_date_gmt] => 2021-01-19 06:56:32
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-08 11:02:27
[post_modified_gmt] => 2021-12-08 11:02:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2442
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[433] => WP_Post Object
(
[ID] => 2441
[post_author] => 5
[post_date] => 2021-01-19 06:48:04
[post_date_gmt] => 2021-01-19 06:48:04
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:47:37
[post_modified_gmt] => 2022-01-27 12:47:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2441
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[434] => WP_Post Object
(
[ID] => 2426
[post_author] => 5
[post_date] => 2020-12-14 15:02:08
[post_date_gmt] => 2020-12-14 15:02:08
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:44:08
[post_modified_gmt] => 2021-12-07 11:44:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[435] => WP_Post Object
(
[ID] => 2424
[post_author] => 5
[post_date] => 2020-12-14 15:01:40
[post_date_gmt] => 2020-12-14 15:01:40
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:46:03
[post_modified_gmt] => 2021-11-23 12:46:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[436] => WP_Post Object
(
[ID] => 1395
[post_author] => 7
[post_date] => 2020-05-30 21:25:33
[post_date_gmt] => 2020-05-30 21:25:33
[post_content] =>
[post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-26 10:16:20
[post_modified_gmt] => 2021-08-26 10:16:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[437] => WP_Post Object
(
[ID] => 1394
[post_author] => 7
[post_date] => 2020-05-30 21:22:44
[post_date_gmt] => 2020-05-30 21:22:44
[post_content] =>
[post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-26 10:15:09
[post_modified_gmt] => 2021-08-26 10:15:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[438] => WP_Post Object
(
[ID] => 1315
[post_author] => 7
[post_date] => 2020-05-23 17:56:03
[post_date_gmt] => 2020-05-23 17:56:03
[post_content] =>
[post_title] => MPP – ViiV, Dolutegravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 13:10:50
[post_modified_gmt] => 2021-11-23 13:10:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[439] => WP_Post Object
(
[ID] => 1313
[post_author] => 7
[post_date] => 2020-05-23 17:55:00
[post_date_gmt] => 2020-05-23 17:55:00
[post_content] =>
[post_title] => MPP – AbbVie, HIV Antiretroviral Sublicense Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 13:30:19
[post_modified_gmt] => 2021-11-30 13:30:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[440] => WP_Post Object
(
[ID] => 1314
[post_author] => 7
[post_date] => 2020-05-23 17:54:57
[post_date_gmt] => 2020-05-23 17:54:57
[post_content] =>
[post_title] => MPP – BMS Sublicense & Tech Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:31:53
[post_modified_gmt] => 2021-12-06 12:31:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[441] => WP_Post Object
(
[ID] => 1308
[post_author] => 7
[post_date] => 2020-05-23 17:17:48
[post_date_gmt] => 2020-05-23 17:17:48
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 15:13:36
[post_modified_gmt] => 2021-11-29 15:13:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[442] => WP_Post Object
(
[ID] => 1309
[post_author] => 7
[post_date] => 2020-05-23 17:17:44
[post_date_gmt] => 2020-05-23 17:17:44
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2joint-undertaking-model-consortium-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-21 13:28:41
[post_modified_gmt] => 2021-06-21 13:28:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1309
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[443] => WP_Post Object
(
[ID] => 1305
[post_author] => 7
[post_date] => 2020-05-23 16:51:40
[post_date_gmt] => 2020-05-23 16:51:40
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 1305
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 07:48:02
[post_modified_gmt] => 2021-11-23 07:48:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1305
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[444] => WP_Post Object
(
[ID] => 1304
[post_author] => 7
[post_date] => 2020-05-23 16:46:37
[post_date_gmt] => 2020-05-23 16:46:37
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 07:50:19
[post_modified_gmt] => 2021-11-23 07:50:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[445] => WP_Post Object
(
[ID] => 1303
[post_author] => 7
[post_date] => 2020-05-23 16:46:30
[post_date_gmt] => 2020-05-23 16:46:30
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 15:17:12
[post_modified_gmt] => 2021-11-29 15:17:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1303
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[446] => WP_Post Object
(
[ID] => 1287
[post_author] => 6
[post_date] => 2020-05-22 23:05:30
[post_date_gmt] => 2020-05-22 23:05:30
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:44:28
[post_modified_gmt] => 2021-12-03 12:44:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[447] => WP_Post Object
(
[ID] => 1285
[post_author] => 6
[post_date] => 2020-05-22 23:01:07
[post_date_gmt] => 2020-05-22 23:01:07
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-21 11:03:29
[post_modified_gmt] => 2021-07-21 11:03:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[448] => WP_Post Object
(
[ID] => 1283
[post_author] => 6
[post_date] => 2020-05-22 22:57:44
[post_date_gmt] => 2020-05-22 22:57:44
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 09:12:54
[post_modified_gmt] => 2022-01-07 09:12:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[449] => WP_Post Object
(
[ID] => 1282
[post_author] => 6
[post_date] => 2020-05-22 22:56:18
[post_date_gmt] => 2020-05-22 22:56:18
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 19:10:36
[post_modified_gmt] => 2022-01-11 19:10:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1282
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[450] => WP_Post Object
(
[ID] => 1281
[post_author] => 6
[post_date] => 2020-05-22 22:55:22
[post_date_gmt] => 2020-05-22 22:55:22
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-20 12:45:11
[post_modified_gmt] => 2021-08-20 12:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1281
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[451] => WP_Post Object
(
[ID] => 1280
[post_author] => 6
[post_date] => 2020-05-22 22:54:32
[post_date_gmt] => 2020-05-22 22:54:32
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 14:31:34
[post_modified_gmt] => 2022-01-18 14:31:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1280
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[452] => WP_Post Object
(
[ID] => 1276
[post_author] => 6
[post_date] => 2020-05-22 22:40:34
[post_date_gmt] => 2020-05-22 22:40:34
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:48:26
[post_modified_gmt] => 2022-01-27 12:48:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1276
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[453] => WP_Post Object
(
[ID] => 1275
[post_author] => 6
[post_date] => 2020-05-22 22:39:41
[post_date_gmt] => 2020-05-22 22:39:41
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:50:21
[post_modified_gmt] => 2022-01-27 12:50:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[454] => WP_Post Object
(
[ID] => 1274
[post_author] => 6
[post_date] => 2020-05-22 22:38:47
[post_date_gmt] => 2020-05-22 22:38:47
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:52:10
[post_modified_gmt] => 2022-01-27 12:52:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[455] => WP_Post Object
(
[ID] => 1273
[post_author] => 6
[post_date] => 2020-05-22 22:37:54
[post_date_gmt] => 2020-05-22 22:37:54
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:55:17
[post_modified_gmt] => 2022-01-27 12:55:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1273
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[456] => WP_Post Object
(
[ID] => 1272
[post_author] => 6
[post_date] => 2020-05-22 22:36:39
[post_date_gmt] => 2020-05-22 22:36:39
[post_content] =>
[post_title] => Boston University Startup Exclusive License Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bu-startup-exclusive-license-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:56:20
[post_modified_gmt] => 2022-01-27 12:56:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[457] => WP_Post Object
(
[ID] => 1271
[post_author] => 6
[post_date] => 2020-05-22 22:34:12
[post_date_gmt] => 2020-05-22 22:34:12
[post_content] =>
[post_title] => WHO Standard Framework MoU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:59:21
[post_modified_gmt] => 2022-01-27 12:59:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1271
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[458] => WP_Post Object
(
[ID] => 1268
[post_author] => 6
[post_date] => 2020-05-22 22:27:54
[post_date_gmt] => 2020-05-22 22:27:54
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 13:20:12
[post_modified_gmt] => 2022-01-27 13:20:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[459] => WP_Post Object
(
[ID] => 1267
[post_author] => 6
[post_date] => 2020-05-22 22:26:39
[post_date_gmt] => 2020-05-22 22:26:39
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 13:02:38
[post_modified_gmt] => 2021-11-23 13:02:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[460] => WP_Post Object
(
[ID] => 1266
[post_author] => 6
[post_date] => 2020-05-22 22:25:16
[post_date_gmt] => 2020-05-22 22:25:16
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 07:55:46
[post_modified_gmt] => 2021-11-23 07:55:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1266
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[461] => WP_Post Object
(
[ID] => 1265
[post_author] => 6
[post_date] => 2020-05-22 22:24:11
[post_date_gmt] => 2020-05-22 22:24:11
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:19:11
[post_modified_gmt] => 2021-11-23 15:19:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1265
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[462] => WP_Post Object
(
[ID] => 1264
[post_author] => 6
[post_date] => 2020-05-22 22:22:55
[post_date_gmt] => 2020-05-22 22:22:55
[post_content] =>
[post_title] => Gilead – Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 13:18:47
[post_modified_gmt] => 2021-12-06 13:18:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[463] => WP_Post Object
(
[ID] => 1263
[post_author] => 6
[post_date] => 2020-05-22 22:20:56
[post_date_gmt] => 2020-05-22 22:20:56
[post_content] =>
[post_title] => MPP – Gilead, TDF License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 13:02:23
[post_modified_gmt] => 2022-01-27 13:02:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[464] => WP_Post Object
(
[ID] => 1262
[post_author] => 6
[post_date] => 2020-05-22 22:18:41
[post_date_gmt] => 2020-05-22 22:18:41
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 13:18:14
[post_modified_gmt] => 2022-01-27 13:18:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1262
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[465] => WP_Post Object
(
[ID] => 1261
[post_author] => 6
[post_date] => 2020-05-22 22:17:34
[post_date_gmt] => 2020-05-22 22:17:34
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 13:23:31
[post_modified_gmt] => 2022-01-27 13:23:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1261
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[466] => WP_Post Object
(
[ID] => 1259
[post_author] => 6
[post_date] => 2020-05-22 22:04:31
[post_date_gmt] => 2020-05-22 22:04:31
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 14:13:45
[post_modified_gmt] => 2022-01-18 14:13:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1259
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[467] => WP_Post Object
(
[ID] => 1258
[post_author] => 6
[post_date] => 2020-05-22 22:03:08
[post_date_gmt] => 2020-05-22 22:03:08
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-20 12:45:23
[post_modified_gmt] => 2021-08-20 12:45:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1258
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[468] => WP_Post Object
(
[ID] => 1254
[post_author] => 6
[post_date] => 2020-05-22 21:44:49
[post_date_gmt] => 2020-05-22 21:44:49
[post_content] =>
[post_title] => Gates Foundation Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-data-materials-sharing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-24 15:24:03
[post_modified_gmt] => 2021-11-24 15:24:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1254
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[469] => WP_Post Object
(
[ID] => 1253
[post_author] => 6
[post_date] => 2020-05-22 21:42:28
[post_date_gmt] => 2020-05-22 21:42:28
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:41:31
[post_modified_gmt] => 2021-08-24 08:41:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[470] => WP_Post Object
(
[ID] => 1249
[post_author] => 6
[post_date] => 2020-05-22 21:37:42
[post_date_gmt] => 2020-05-22 21:37:42
[post_content] =>
[post_title] => MPP License Agreement with Gilead
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 15:54:34
[post_modified_gmt] => 2021-11-30 15:54:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[471] => WP_Post Object
(
[ID] => 1248
[post_author] => 6
[post_date] => 2020-05-22 21:36:47
[post_date_gmt] => 2020-05-22 21:36:47
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-12 14:17:58
[post_modified_gmt] => 2022-01-12 14:17:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1248
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[472] => WP_Post Object
(
[ID] => 1247
[post_author] => 6
[post_date] => 2020-05-22 21:33:54
[post_date_gmt] => 2020-05-22 21:33:54
[post_content] =>
[post_title] => WHO Confidential Disclosure Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-mutual-confidential-disclosure-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-24 15:35:46
[post_modified_gmt] => 2021-11-24 15:35:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1247
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[473] => WP_Post Object
(
[ID] => 1245
[post_author] => 6
[post_date] => 2020-05-22 21:32:14
[post_date_gmt] => 2020-05-22 21:32:14
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 07:26:41
[post_modified_gmt] => 2021-11-23 07:26:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1245
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[474] => WP_Post Object
(
[ID] => 1243
[post_author] => 6
[post_date] => 2020-05-22 21:29:10
[post_date_gmt] => 2020-05-22 21:29:10
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 09:45:19
[post_modified_gmt] => 2022-01-19 09:45:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1243
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[475] => WP_Post Object
(
[ID] => 1242
[post_author] => 6
[post_date] => 2020-05-22 21:26:04
[post_date_gmt] => 2020-05-22 21:26:04
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 16:09:57
[post_modified_gmt] => 2021-11-22 16:09:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[476] => WP_Post Object
(
[ID] => 1240
[post_author] => 6
[post_date] => 2020-05-22 21:22:47
[post_date_gmt] => 2020-05-22 21:22:47
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 11:29:41
[post_modified_gmt] => 2022-01-07 11:29:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[477] => WP_Post Object
(
[ID] => 1239
[post_author] => 6
[post_date] => 2020-05-22 21:21:49
[post_date_gmt] => 2020-05-22 21:21:49
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:52:13
[post_modified_gmt] => 2021-11-22 15:52:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1239
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[478] => WP_Post Object
(
[ID] => 1238
[post_author] => 6
[post_date] => 2020-05-22 21:20:51
[post_date_gmt] => 2020-05-22 21:20:51
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:59:46
[post_modified_gmt] => 2022-01-24 12:59:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1238
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[479] => WP_Post Object
(
[ID] => 1237
[post_author] => 6
[post_date] => 2020-05-22 21:19:08
[post_date_gmt] => 2020-05-22 21:19:08
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 13:00:19
[post_modified_gmt] => 2022-01-24 13:00:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1237
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[480] => WP_Post Object
(
[ID] => 1235
[post_author] => 6
[post_date] => 2020-05-22 21:01:14
[post_date_gmt] => 2020-05-22 21:01:14
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 14:07:30
[post_modified_gmt] => 2021-12-06 14:07:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[481] => WP_Post Object
(
[ID] => 1233
[post_author] => 6
[post_date] => 2020-05-22 21:00:08
[post_date_gmt] => 2020-05-22 21:00:08
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 11:39:16
[post_modified_gmt] => 2022-02-11 11:39:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1233
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[482] => WP_Post Object
(
[ID] => 1229
[post_author] => 6
[post_date] => 2020-05-22 20:51:35
[post_date_gmt] => 2020-05-22 20:51:35
[post_content] =>
[post_title] => MPP – BMS – Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 10:45:22
[post_modified_gmt] => 2021-12-07 10:45:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[483] => WP_Post Object
(
[ID] => 1228
[post_author] => 6
[post_date] => 2020-05-22 20:49:20
[post_date_gmt] => 2020-05-22 20:49:20
[post_content] =>
[post_title] => MPP – Gilead, TDF License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 15:54:04
[post_modified_gmt] => 2021-11-30 15:54:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[484] => WP_Post Object
(
[ID] => 1227
[post_author] => 6
[post_date] => 2020-05-22 20:48:27
[post_date_gmt] => 2020-05-22 20:48:27
[post_content] =>
[post_title] => WHO – Manufacturer, Ebola Products Collaboration LOA Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ebola-who-manufacturer-loa-annex
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 12:10:29
[post_modified_gmt] => 2021-12-07 12:10:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1227
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[485] => WP_Post Object
(
[ID] => 1226
[post_author] => 6
[post_date] => 2020-05-22 20:47:05
[post_date_gmt] => 2020-05-22 20:47:05
[post_content] =>
[post_title] => WHO Template Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-22 14:45:07
[post_modified_gmt] => 2022-01-22 14:45:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1226
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[486] => WP_Post Object
(
[ID] => 1225
[post_author] => 6
[post_date] => 2020-05-22 20:43:20
[post_date_gmt] => 2020-05-22 20:43:20
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 13:10:08
[post_modified_gmt] => 2022-01-24 13:10:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1225
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[487] => WP_Post Object
(
[ID] => 1221
[post_author] => 6
[post_date] => 2020-05-22 20:09:53
[post_date_gmt] => 2020-05-22 20:09:53
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfpi3-template-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 09:23:06
[post_modified_gmt] => 2022-02-28 09:23:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[488] => WP_Post Object
(
[ID] => 1220
[post_author] => 6
[post_date] => 2020-05-22 20:05:59
[post_date_gmt] => 2020-05-22 20:05:59
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 15:23:28
[post_modified_gmt] => 2022-01-11 15:23:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[489] => WP_Post Object
(
[ID] => 1218
[post_author] => 6
[post_date] => 2020-05-22 20:04:53
[post_date_gmt] => 2020-05-22 20:04:53
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 07:30:07
[post_modified_gmt] => 2021-08-24 07:30:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[490] => WP_Post Object
(
[ID] => 1215
[post_author] => 6
[post_date] => 2020-05-22 19:56:47
[post_date_gmt] => 2020-05-22 19:56:47
[post_content] =>
[post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => edctp2-policy-on-clinical-trials-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 16:15:05
[post_modified_gmt] => 2021-12-06 16:15:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[491] => WP_Post Object
(
[ID] => 1214
[post_author] => 6
[post_date] => 2020-05-22 19:55:41
[post_date_gmt] => 2020-05-22 19:55:41
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:54:05
[post_modified_gmt] => 2021-11-22 15:54:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[492] => WP_Post Object
(
[ID] => 1211
[post_author] => 6
[post_date] => 2020-05-22 19:50:22
[post_date_gmt] => 2020-05-22 19:50:22
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 15:07:54
[post_modified_gmt] => 2021-11-29 15:07:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[493] => WP_Post Object
(
[ID] => 1207
[post_author] => 6
[post_date] => 2020-05-22 19:42:36
[post_date_gmt] => 2020-05-22 19:42:36
[post_content] =>
[post_title] => MPP – Pfizer, Sutezolid License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 09:20:12
[post_modified_gmt] => 2022-04-01 09:20:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[494] => WP_Post Object
(
[ID] => 1206
[post_author] => 6
[post_date] => 2020-05-22 19:37:27
[post_date_gmt] => 2020-05-22 19:37:27
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-global-access-commitment-and-humanitarian-license
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:41:46
[post_modified_gmt] => 2022-03-28 10:41:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[495] => WP_Post Object
(
[ID] => 1200
[post_author] => 6
[post_date] => 2020-05-22 19:35:05
[post_date_gmt] => 2020-05-22 19:35:05
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:26:24
[post_modified_gmt] => 2021-11-29 14:26:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[496] => WP_Post Object
(
[ID] => 1205
[post_author] => 6
[post_date] => 2020-05-22 19:33:17
[post_date_gmt] => 2020-05-22 19:33:17
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:19:08
[post_modified_gmt] => 2022-03-28 10:19:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[497] => WP_Post Object
(
[ID] => 1204
[post_author] => 6
[post_date] => 2020-05-22 19:31:46
[post_date_gmt] => 2020-05-22 19:31:46
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-29 12:53:24
[post_modified_gmt] => 2022-03-29 12:53:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[498] => WP_Post Object
(
[ID] => 1203
[post_author] => 6
[post_date] => 2020-05-22 19:30:52
[post_date_gmt] => 2020-05-22 19:30:52
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-07-07 16:21:41
[post_modified_gmt] => 2021-07-07 16:21:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[499] => WP_Post Object
(
[ID] => 1202
[post_author] => 6
[post_date] => 2020-05-22 19:28:49
[post_date_gmt] => 2020-05-22 19:28:49
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:52:26
[post_modified_gmt] => 2021-08-10 10:52:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[500] => WP_Post Object
(
[ID] => 1201
[post_author] => 6
[post_date] => 2020-05-22 19:26:29
[post_date_gmt] => 2020-05-22 19:26:29
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:39:51
[post_modified_gmt] => 2022-03-28 10:39:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[501] => WP_Post Object
(
[ID] => 1199
[post_author] => 6
[post_date] => 2020-05-22 19:21:57
[post_date_gmt] => 2020-05-22 19:21:57
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 08:55:34
[post_modified_gmt] => 2022-04-01 08:55:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[502] => WP_Post Object
(
[ID] => 1198
[post_author] => 6
[post_date] => 2020-05-22 19:12:54
[post_date_gmt] => 2020-05-22 19:12:54
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-30 12:44:48
[post_modified_gmt] => 2022-03-30 12:44:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[503] => WP_Post Object
(
[ID] => 1190
[post_author] => 6
[post_date] => 2020-05-22 01:59:48
[post_date_gmt] => 2020-05-22 01:59:48
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 10:44:40
[post_modified_gmt] => 2022-03-31 10:44:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[504] => WP_Post Object
(
[ID] => 1187
[post_author] => 6
[post_date] => 2020-05-22 01:56:10
[post_date_gmt] => 2020-05-22 01:56:10
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:16:05
[post_modified_gmt] => 2022-03-28 10:16:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[505] => WP_Post Object
(
[ID] => 1185
[post_author] => 6
[post_date] => 2020-05-22 00:10:01
[post_date_gmt] => 2020-05-22 00:10:01
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-20 12:45:45
[post_modified_gmt] => 2021-08-20 12:45:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1185
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[506] => WP_Post Object
(
[ID] => 1184
[post_author] => 6
[post_date] => 2020-05-22 00:08:17
[post_date_gmt] => 2020-05-22 00:08:17
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:26:51
[post_modified_gmt] => 2021-11-29 14:26:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[507] => WP_Post Object
(
[ID] => 1183
[post_author] => 6
[post_date] => 2020-05-22 00:06:26
[post_date_gmt] => 2020-05-22 00:06:26
[post_content] =>
[post_title] => MPP – AbbVie, HIV Antiretroviral Sublicense Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-abbvie
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 10:11:47
[post_modified_gmt] => 2021-12-07 10:11:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[508] => WP_Post Object
(
[ID] => 1182
[post_author] => 6
[post_date] => 2020-05-22 00:02:42
[post_date_gmt] => 2020-05-22 00:02:42
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 10:28:10
[post_modified_gmt] => 2022-01-19 10:28:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1182
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[509] => WP_Post Object
(
[ID] => 1178
[post_author] => 6
[post_date] => 2020-05-21 23:55:50
[post_date_gmt] => 2020-05-21 23:55:50
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 15:12:42
[post_modified_gmt] => 2021-11-29 15:12:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[510] => WP_Post Object
(
[ID] => 1177
[post_author] => 6
[post_date] => 2020-05-21 23:53:56
[post_date_gmt] => 2020-05-21 23:53:56
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:14:41
[post_modified_gmt] => 2021-12-03 12:14:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1177
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[511] => WP_Post Object
(
[ID] => 1176
[post_author] => 6
[post_date] => 2020-05-21 23:52:12
[post_date_gmt] => 2020-05-21 23:52:12
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 14:35:06
[post_modified_gmt] => 2022-01-24 14:35:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[512] => WP_Post Object
(
[ID] => 1171
[post_author] => 6
[post_date] => 2020-05-21 23:33:24
[post_date_gmt] => 2020-05-21 23:33:24
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 15:06:26
[post_modified_gmt] => 2021-11-29 15:06:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[513] => WP_Post Object
(
[ID] => 1170
[post_author] => 6
[post_date] => 2020-05-21 23:28:59
[post_date_gmt] => 2020-05-21 23:28:59
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2020-08-06 07:46:46
[post_modified_gmt] => 2020-08-06 07:46:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1170
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[514] => WP_Post Object
(
[ID] => 1168
[post_author] => 6
[post_date] => 2020-05-21 23:26:48
[post_date_gmt] => 2020-05-21 23:26:48
[post_content] =>
[post_title] => NIH - Non-Profit, Model License Agreement Terms
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-model-license-agreement-for-use-by-non-profit-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-17 12:22:07
[post_modified_gmt] => 2021-08-17 12:22:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1168
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[515] => WP_Post Object
(
[ID] => 1166
[post_author] => 6
[post_date] => 2020-05-21 23:26:07
[post_date_gmt] => 2020-05-21 23:26:07
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:44:46
[post_modified_gmt] => 2021-12-07 11:44:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1166
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[516] => WP_Post Object
(
[ID] => 1165
[post_author] => 6
[post_date] => 2020-05-21 23:23:57
[post_date_gmt] => 2020-05-21 23:23:57
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 15:17:57
[post_modified_gmt] => 2021-11-29 15:17:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[517] => WP_Post Object
(
[ID] => 1164
[post_author] => 6
[post_date] => 2020-05-21 23:22:37
[post_date_gmt] => 2020-05-21 23:22:37
[post_content] =>
[post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => autm-model-iia
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 09:26:25
[post_modified_gmt] => 2022-01-19 09:26:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1164
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[518] => WP_Post Object
(
[ID] => 1162
[post_author] => 6
[post_date] => 2020-05-21 23:19:43
[post_date_gmt] => 2020-05-21 23:19:43
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:02:07
[post_modified_gmt] => 2021-12-06 12:02:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1162
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[519] => WP_Post Object
(
[ID] => 1160
[post_author] => 6
[post_date] => 2020-05-21 23:18:03
[post_date_gmt] => 2020-05-21 23:18:03
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => aridis-path-vaccine-formulation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 08:38:16
[post_modified_gmt] => 2022-01-07 08:38:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[520] => WP_Post Object
(
[ID] => 1159
[post_author] => 6
[post_date] => 2020-05-21 23:14:15
[post_date_gmt] => 2020-05-21 23:14:15
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 15:23:48
[post_modified_gmt] => 2021-12-06 15:23:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[521] => WP_Post Object
(
[ID] => 1158
[post_author] => 6
[post_date] => 2020-05-21 23:12:13
[post_date_gmt] => 2020-05-21 23:12:13
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 15:42:23
[post_modified_gmt] => 2021-12-06 15:42:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[522] => WP_Post Object
(
[ID] => 1156
[post_author] => 6
[post_date] => 2020-05-21 23:10:39
[post_date_gmt] => 2020-05-21 23:10:39
[post_content] =>
[post_title] => WHO Standard Framework Memorandum of Understanding
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 12:11:17
[post_modified_gmt] => 2021-12-07 12:11:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[523] => WP_Post Object
(
[ID] => 1155
[post_author] => 6
[post_date] => 2020-05-21 23:09:39
[post_date_gmt] => 2020-05-21 23:09:39
[post_content] =>
[post_title] => WHO Template Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => template-collaboration-agreement-with-who
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-18 13:24:40
[post_modified_gmt] => 2021-08-18 13:24:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[524] => WP_Post Object
(
[ID] => 1150
[post_author] => 6
[post_date] => 2020-05-21 22:53:25
[post_date_gmt] => 2020-05-21 22:53:25
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 18:54:41
[post_modified_gmt] => 2022-01-11 18:54:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[525] => WP_Post Object
(
[ID] => 1147
[post_author] => 6
[post_date] => 2020-05-21 22:50:33
[post_date_gmt] => 2020-05-21 22:50:33
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-17 14:32:11
[post_modified_gmt] => 2021-06-17 14:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[526] => WP_Post Object
(
[ID] => 1145
[post_author] => 6
[post_date] => 2020-05-21 22:48:08
[post_date_gmt] => 2020-05-21 22:48:08
[post_content] =>
[post_title] => Gilead – Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 13:18:11
[post_modified_gmt] => 2021-12-06 13:18:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1145
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[527] => WP_Post Object
(
[ID] => 1143
[post_author] => 6
[post_date] => 2020-05-21 22:46:30
[post_date_gmt] => 2020-05-21 22:46:30
[post_content] =>
[post_title] => MPP - Gilead, TDF License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 15:56:49
[post_modified_gmt] => 2021-11-30 15:56:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1143
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[528] => WP_Post Object
(
[ID] => 1141
[post_author] => 6
[post_date] => 2020-05-21 22:43:46
[post_date_gmt] => 2020-05-21 22:43:46
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:19:17
[post_modified_gmt] => 2021-12-03 12:19:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[529] => WP_Post Object
(
[ID] => 1140
[post_author] => 6
[post_date] => 2020-05-21 22:37:27
[post_date_gmt] => 2020-05-21 22:37:27
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 14:04:19
[post_modified_gmt] => 2021-12-06 14:04:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[530] => WP_Post Object
(
[ID] => 1139
[post_author] => 6
[post_date] => 2020-05-21 22:35:04
[post_date_gmt] => 2020-05-21 22:35:04
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:27:18
[post_modified_gmt] => 2021-11-29 14:27:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[531] => WP_Post Object
(
[ID] => 1137
[post_author] => 6
[post_date] => 2020-05-21 22:22:50
[post_date_gmt] => 2020-05-21 22:22:50
[post_content] =>
[post_title] => Gilead – Indian Generic Manufacturers, HCV License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:52:19
[post_modified_gmt] => 2021-11-23 12:52:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[532] => WP_Post Object
(
[ID] => 1135
[post_author] => 6
[post_date] => 2020-05-21 22:19:46
[post_date_gmt] => 2020-05-21 22:19:46
[post_content] =>
[post_title] => NIH - Non-Profit, Model License Agreement Terms
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-model-license-agreement-for-use-by-non-profit
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-17 12:21:52
[post_modified_gmt] => 2021-08-17 12:21:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[533] => WP_Post Object
(
[ID] => 1134
[post_author] => 6
[post_date] => 2020-05-21 22:00:36
[post_date_gmt] => 2020-05-21 22:00:36
[post_content] =>
[post_title] => CAVD Data & Materials Sharing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cavd-data-materials-sharing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:13:49
[post_modified_gmt] => 2021-11-22 15:13:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[534] => WP_Post Object
(
[ID] => 1132
[post_author] => 6
[post_date] => 2020-05-21 21:58:10
[post_date_gmt] => 2020-05-21 21:58:10
[post_content] =>
[post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-joint-undertaking-model-consortium-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 07:53:58
[post_modified_gmt] => 2021-11-23 07:53:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1132
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[535] => WP_Post Object
(
[ID] => 1128
[post_author] => 6
[post_date] => 2020-05-21 21:50:04
[post_date_gmt] => 2020-05-21 21:50:04
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 15:19:03
[post_modified_gmt] => 2021-11-29 15:19:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[536] => WP_Post Object
(
[ID] => 1127
[post_author] => 6
[post_date] => 2020-05-21 21:47:49
[post_date_gmt] => 2020-05-21 21:47:49
[post_content] =>
[post_title] => Boston University Startup Exclusive License Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bu-startup-exclusive-license
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:49:28
[post_modified_gmt] => 2021-12-03 10:49:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[537] => WP_Post Object
(
[ID] => 1125
[post_author] => 6
[post_date] => 2020-05-21 21:44:59
[post_date_gmt] => 2020-05-21 21:44:59
[post_content] =>
[post_title] => MPP – AbbVie, HIV Antiretroviral Sublicense Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 10:12:44
[post_modified_gmt] => 2021-12-07 10:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[538] => WP_Post Object
(
[ID] => 1124
[post_author] => 6
[post_date] => 2020-05-21 21:41:21
[post_date_gmt] => 2020-05-21 21:41:21
[post_content] =>
[post_title] => MPP – BMS Sublicense & Tech Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 15:10:50
[post_modified_gmt] => 2021-11-30 15:10:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[539] => WP_Post Object
(
[ID] => 1123
[post_author] => 6
[post_date] => 2020-05-21 21:37:52
[post_date_gmt] => 2020-05-21 21:37:52
[post_content] =>
[post_title] => MPP – ViiV, Dolutegravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:32:09
[post_modified_gmt] => 2021-12-07 11:32:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[540] => WP_Post Object
(
[ID] => 1122
[post_author] => 6
[post_date] => 2020-05-21 21:30:19
[post_date_gmt] => 2020-05-21 21:30:19
[post_content] =>
[post_title] => MPP – BMS – Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 09:04:02
[post_modified_gmt] => 2022-04-01 09:04:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[541] => WP_Post Object
(
[ID] => 1118
[post_author] => 6
[post_date] => 2020-05-21 21:24:00
[post_date_gmt] => 2020-05-21 21:24:00
[post_content] =>
[post_title] => MPP – AbbVie, HIV Antiretroviral License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-abbvie
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:55:43
[post_modified_gmt] => 2021-12-03 12:55:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1118
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[542] => WP_Post Object
(
[ID] => 1117
[post_author] => 6
[post_date] => 2020-05-21 21:17:31
[post_date_gmt] => 2020-05-21 21:17:31
[post_content] =>
[post_title] => MPP – University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpps-license-agreement-with-university-of-liverpool
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:20:41
[post_modified_gmt] => 2021-12-07 11:20:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[543] => WP_Post Object
(
[ID] => 1114
[post_author] => 6
[post_date] => 2020-05-21 21:13:15
[post_date_gmt] => 2020-05-21 21:13:15
[post_content] =>
[post_title] => MPP – Gilead, TDF License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-license-agreement-with-gilead
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 15:52:53
[post_modified_gmt] => 2021-11-30 15:52:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1114
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[544] => WP_Post Object
(
[ID] => 1113
[post_author] => 6
[post_date] => 2020-05-21 21:09:47
[post_date_gmt] => 2020-05-21 21:09:47
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d-15
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-18 10:00:59
[post_modified_gmt] => 2021-08-18 10:00:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[545] => WP_Post Object
(
[ID] => 1112
[post_author] => 6
[post_date] => 2020-05-21 21:06:05
[post_date_gmt] => 2020-05-21 21:06:05
[post_content] =>
[post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 14:03:43
[post_modified_gmt] => 2021-12-06 14:03:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1112
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[546] => WP_Post Object
(
[ID] => 1111
[post_author] => 6
[post_date] => 2020-05-21 21:03:23
[post_date_gmt] => 2020-05-21 21:03:23
[post_content] =>
[post_title] => IMI 1 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-1-model-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-17 14:30:40
[post_modified_gmt] => 2021-06-17 14:30:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[547] => WP_Post Object
(
[ID] => 1108
[post_author] => 6
[post_date] => 2020-05-21 20:59:47
[post_date_gmt] => 2020-05-21 20:59:47
[post_content] =>
[post_title] => WHO Template Material Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-template-material-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:18:49
[post_modified_gmt] => 2021-11-23 15:18:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1108
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[548] => WP_Post Object
(
[ID] => 1107
[post_author] => 6
[post_date] => 2020-05-21 20:57:25
[post_date_gmt] => 2020-05-21 20:57:25
[post_content] =>
[post_title] => Lambert Toolkit, Consortium Agreement D Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lambert-agreement-d
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:17:25
[post_modified_gmt] => 2021-12-03 12:17:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1107
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[549] => WP_Post Object
(
[ID] => 996
[post_author] => 7
[post_date] => 2020-05-18 19:58:18
[post_date_gmt] => 2020-05-18 19:58:18
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 11:36:22
[post_modified_gmt] => 2021-12-03 11:36:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 550
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:09:54
[post_modified_gmt] => 2022-05-24 09:09:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 550
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => e01c85d590491d7274db542269a3a521
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_agreement_q_rslts] =>
[text_provision_q_rslts] =>
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:09:54
[post_modified_gmt] => 2022-05-24 09:09:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4807
[post_author] => 5
[post_date] => 2022-05-24 09:02:55
[post_date_gmt] => 2022-05-24 09:02:55
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:02:55
[post_modified_gmt] => 2022-05-24 09:02:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4806
[post_author] => 5
[post_date] => 2022-05-24 08:59:08
[post_date_gmt] => 2022-05-24 08:59:08
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:08
[post_modified_gmt] => 2022-05-24 08:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4805
[post_author] => 5
[post_date] => 2022-05-24 08:53:12
[post_date_gmt] => 2022-05-24 08:53:12
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:42
[post_modified_gmt] => 2022-05-24 08:59:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4804
[post_author] => 5
[post_date] => 2022-05-24 08:40:15
[post_date_gmt] => 2022-05-24 08:40:15
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:53:51
[post_modified_gmt] => 2022-05-24 08:53:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4802
[post_author] => 5
[post_date] => 2022-05-24 08:24:23
[post_date_gmt] => 2022-05-24 08:24:23
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:24:23
[post_modified_gmt] => 2022-05-24 08:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4801
[post_author] => 5
[post_date] => 2022-05-24 08:19:21
[post_date_gmt] => 2022-05-24 08:19:21
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:19:21
[post_modified_gmt] => 2022-05-24 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4800
[post_author] => 5
[post_date] => 2022-05-24 08:07:39
[post_date_gmt] => 2022-05-24 08:07:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:08:30
[post_modified_gmt] => 2022-05-24 08:08:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4797
[post_author] => 5
[post_date] => 2022-05-23 13:54:57
[post_date_gmt] => 2022-05-23 13:54:57
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 13:54:57
[post_modified_gmt] => 2022-05-23 13:54:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4796
[post_author] => 5
[post_date] => 2022-05-23 13:54:05
[post_date_gmt] => 2022-05-23 13:54:05
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:21:34
[post_modified_gmt] => 2022-05-23 14:21:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4704
[post_author] => 5
[post_date] => 2022-04-26 15:08:03
[post_date_gmt] => 2022-04-26 15:08:03
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:08:03
[post_modified_gmt] => 2022-04-26 15:08:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4704
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 4703
[post_author] => 5
[post_date] => 2022-04-26 14:56:55
[post_date_gmt] => 2022-04-26 14:56:55
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:56:55
[post_modified_gmt] => 2022-04-26 14:56:55
[post_content_filtered] =>
[post_parent] => 0